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ABSTRACT
Obesity has become a widespread concern to human health largely over
the past three decades. It is thought that obesity is associated with the over
consumption of calorically dense diets. The rewarding value of food is mediated
through the mesolimbic dopamine system, though is less understood how
appetitive control circuits relay information to existing reward circuitry. The
adiposity signaling hormone, leptin, is a critical mediator of food intake and fat
storage. Leptin signaling, via the long form of the leptin receptor (LepRb), is
predominantly carried out within the hypothalamus. Leptin action specific to the
lateral hypothalamus area (LHA) modulates reward function via direct and
indirect inhibition of reward circuitry. Here, I have identified a novel leptin
receptor population within the LHA that co-expresses the inhibitory neuropeptide
galanin (termed Gal-LepRb neurons). To investigate the physiological function of
leptin through Gal-LepRb neurons, we selectively deleted LepRb in galanin
neurons (referred to as Gal-LepRbKO mice). In a two-bottle-choice paradigm, I
assessed nutrient selection for isocaloric lipid and sucrose solutions.
Interestingly, Gal-LepRbKO mice demonstrated a significant preference for the
sucrose solution and decreased lipid intake compared to controls. Moreover,
Gal-LepRbKO mice displayed stronger motivation to work for a sucrose treat. My
data further indicate that Gal-LepRb neurons are inhibitory acting neurons that
are stimulated by leptin. Gal-LepRb neurons strongly innervate local orexin
neurons and noradrenergic neurons in the locus coeruleus (LC). Intriguingly,
orexin neurons also strongly innervate the LC, and activation of orexin neurons
	
  
	
  

xiii

correlates with motivational and food-seeking behaviors. My data also show that
orexin neurons express the Gi-coupled GPCR galanin 1-receptor (GalR1),
validating the cellular ability of orexin neurons to respond to galanin. In
summary, we have characterized a novel population of LHA LepRb neurons and
propose that leptin-mediated inhibition of orexin neurons, possibly via inhibitory
galanin-GalR1 signaling, regulates the reward value of nutrients.
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CHAPTER 1. GENERAL INTRODUCTION
1.1 LEPTIN
1.1.1 Leptin and energy balance. Leptin is a 16kD peptide secreted from
adipocytes and largely communicates information concerning energy stores to the
brain (Zhang et al. 1994, Elmquist, Maratos-Flier, et al. 1998, Friedman 1998).
Circulating leptin levels are correlated with the amount of fat mass present within an
organism (Frederich et al. 1995, Maffei et al. 1995) and fasting-induced drops in
leptin levels elicits a strong feeding response (Maffei et al. 1995). Leptin plays a
critical role in energy balance regulation as mice lacking the capability to produce
leptin, known as ob/ob mice, are morbidly obese, show marked increases in food
intake (hyperphagia) and exhibit numerous metabolic-associated dysfunctions
(Zhang et al. 1994, Montague et al. 1997, Clement et al. 1998). Although ob/ob
mice exhibit an extreme obesity phenotype, the absence of leptin triggers a
starvation signal thereby inducing a potent feeding response. Accordingly,
administration of recombinant leptin to ob/ob mice and leptin deficient humans fully
reverses obesity and corrects co-morbidity metabolic effects (Halaas et al. 1995,
Ozata, Ozdemir, and Licinio 1999, Farooqi et al. 2002, Farooqi 2008). When first
discovered, leptin was expected to be the long anticipated cure for obesity since
treatment with recombinant leptin reduced body fat mass in both lean and ob/ob
mice (Halaas et al. 1995). However, this was not the case as diet-induced obese
animals and obese humans exhibit markedly increased circulating leptin levels
(Maffei et al. 1995, Considine et al. 1996, Frederich et al. 1995) and leptin
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treatments only marginally decreased body weight in obese humans and rodents
(Halaas et al. 1997, Heymsfield et al. 1999). These findings suggest a form of
desensitization to leptin in the obese state. Therefore, it is important we unravel the
diversity of leptin action in order to develop effective treatments to counteract or
prevent obesity-induced leptin resistance.
1.1.2 Leptin receptor signaling and distribution. The leptin receptor gene
encodes five alternatively spliced forms of the leptin receptor (Lep-Ra, Lep-Rb, LepRc, Lep-Rd, and Lep-Re) (Tartaglia et al. 1995, Lee et al. 1996). The LepR-b form
is considered the long form of the leptin receptor due to its long cytoplasmic domain
containing various motifs required for leptin-mediated signaling. Mutations in the
long form of the leptin receptor, LepRb, result in an obese phenotype that strongly
resembles the ob/ob mouse (Li et al. 1998). Thus, the anorexigenic (appetite
decreasing) effects of leptin are predominantly carried out by LepRb. Leptininduced activation of the LepRb relies on the activity of janus kinase-2 (JAK2) which
phosphorylates tyrosine residues associated with the receptor (Bjorbaek et al.
2001). In vivo, leptin-induced activation of the LepRb stimulates JAK2-mediated
phosphorylation of the signal transducer and activator of transcription-3 (STAT3) as
shown in Figure 1.1 (Vaisse et al. 1996). Phosphorylated-STAT3 (pSTAT3) then
dimerizes and translocates into the nucleus prompting transcription of leptin
responsive genes (Vaisse et al. 1996, Bjorbaek et al. 2001, Banks et al. 2000).
Activation of STAT3 is crucial for leptin’s effects on body weight regulation, as
mutations in tyrosine 1138 of the LepRb (the site of STAT3 phosphorylation; Figure
1.1) leads to hyperphagia and obesity (Bates et al. 2003). Leptin signaling via
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LepRb also leads to tyrosine phosphorylation of the tyrosine phosphatase SHP-2
which decreases the activity level of JAK2 to down-regulate LepRb activation
(Carpenter et al. 1998). Additionally, the induction of downstream leptin effector
SOCS-3 (suppressor of cytokine signaling-3) is also involved in negative feedback
to the activated LepRb and is largely implicated in leptin resistance (Bjorbaek et al.
1998).

	
  
Figure 1.1 Leptin-induced activation of pSTAT3 upon binding to the long form of the
leptin receptor (LepRb).
In rodents and humans, leptin receptors are expressed in various nuclei
throughout the central nervous system, but most prominent leptin action occurs
within the hypothalamus. The hypothalamus is the brain region largely recognized
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for energy balance regulation. Within the hypothalamus, LepRbs are expressed in
the arcuate nucleus (ARC), ventromedial hypothalamus (VMH), dorsomedial
hypothalamus (DMH), paraventricular hypothalamus (PVN) and the lateral
hypothalamus area (LHA) (Mercer et al. 1996, Fei et al. 1997, Elmquist, Bjorbaek,
et al. 1998). As mentioned, the effects of leptin are generally associated with
weight loss and reduced food intake (anorexia). However, it is now widely
acknowledged that the anatomical location of LepRb-expressing neurons dictates a
very specific contribution to whole body energy balance (Berthoud 2007, Dhillon et
al. 2006, van de Wall et al. 2008, Morton et al. 2003, Gao and Horvath 2007). For
example, proopiomelanocortin (POMC)-expressing LepRb neurons in the ARC are
critical for glucose homeostasis (Leinninger 2011, Balthasar et al. 2004, Berthoud
2007, Elmquist et al. 2005, Morton et al. 2003, van de Wall et al. 2008), while
glutamatergic (excitatory) LepRb neurons in the DMH are involved in body
temperature regulation (Zhang et al. 2011). Recently, LepRbs in the lateral
hypothalamus area (LHA) that express the inhibitory neurotransmitter, gammaaminobutyric acid (GABA), have been highlighted for their role in reward function
(Leinninger 2011, Leinninger et al. 2009). Taken together, the ability of leptin to
regulate energy balance involves a complex integration of numerous and
functionally distinct LepRb populations, many of which, have not been thoroughly
characterized or possibly even identified.
1.2 LEPTIN INFLUENCES REWARD CIRCUITS
1.2.1 LHA-LepRb neurons and the mesolimbic dopaminergic system.
The LHA has long been established for regulating reward-driven behaviors and
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LHA neurons are highly responsive to food cues (Rolls, Burton, and Mora 1976,
1980). Early intracranial self-stimulation experiments revealed that rats will
continuously perform a licking task in order to activate an electrode implanted into
the LHA (Nakamura and Ono 1986). This suggests that general stimulation of LHA
neurons induces a form of pleasure. This effect also holds true for natural rewards
as a large population of LHA neurons are stimulated when animals perform the
same licking task for a glucose solution (Nakamura and Ono 1986). The LHA elicits
these reward responses via activation of the mesolimbic dopaminergic system.
Neurons in the LHA send dense projections to many limbic structures (ventral
tegmental area, striatum, and pallidum) which act as critical regulators of motivated
behavior. Namely, the mesolimbic dopaminergic system is comprised of dopamine
(DA) neurons within the ventral tegmental area (VTA) that send long axonal
projections to the nucleus accumbens (NAc; Figure 1.2). Activation of the VTA-DA
neurons and subsequent DA release within the NAc (VTAàNAc dopamine release
termed mesoaccumbal DA) is believed to be the pathway responsible for
encouraging reward-driven and motivated behaviors (Goto and Grace 2005,
Berridge and Robinson 1998, Pecina et al. 2003, Ostlund et al. 2011). Previous
experiments showed that leptin administration dampened motivated responses for
LHA intracranial self-stimulation (Fulton, Woodside, and Shizgal 2000). Thus,
circuits governing reward-motivated behaviors appear to converge with leptin
signaling pathways.
From a survival standpoint, it makes sense that pathways dictating nutrient
intake would converge into the mesolimbic DA system to reinforce food seeking and

	
  
	
  

5

appetitive behaviors when energy stores are low. Due to their high-calorie content,
sugar and fat-rich foods have evolved as potent stimulators of mesoaccumbal DA
release (Hajnal, Smith, and Norgren 2004, Rada, Avena, and Hoebel 2005, Liang,
Hajnal, and Norgren 2006). Thus, the evoked intensity of DA release is believed to
encode the motivational properties (incentive value) for food rewards (Reilly 1999,
Sclafani and Ackroff 2003, Wojnicki, Babbs, and Corwin 2010, Yoneda et al. 2007).
Likewise, the anorexigenic effects of leptin are mediated, in part, through the
inhibition of the mesolimbic DA system. Electrophysiological studies in brain slice
preparations demonstrated that leptin inhibits firing of VTA DA neurons (Hommel et
al. 2006). In behavioral studies, leptin was shown to attenuate sucrose seeking and
sucrose consumption in rats (Figlewicz et al. 2001, Figlewicz et al. 2006). Together,
these observations suggest that leptin’s inhibitory influence over DA neurons acts to
decrease the incentive value of a food reward. On the contrary, electrically
stimulated DA release in the NAc is markedly reduced in leptin deficient ob/ob mice
(Fulton et al. 2006). Therefore, the function of leptin is contradictory in the literature;
suggesting either inhibitory or stimulatory leptin action on VTA DA neurons.
Clarifying the role of leptin in the regulation of the mesolimbic dopaminergic system
is critical to understand the mechanism by which leptin modulates nutrient reward.
Recent data indicates that LHA LepRb neurons project to VTA neurons and
modulate food intake (Leinninger et al. 2009). The established LHA-LepRb circuit,
shown in Figure 1.2, illustrates that leptin signaling in the LHA would directly
modulate mesoaccumbal DA function. Whether leptin would induce its effects
through inhibition or stimulation of mesoaccumbal DA release is matter that
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remains controversial. Therefore, determining the specific contribution of LHALepRb neurons in the regulation the mesolimbic dopamine system would provide
a functional pathway for understanding how the nutritional state of the body
regulates reward-based feeding.

LV

4V

VTA

DA Release

NAc

ORX
LHA
LepRb

Figure 1.2 Schematic illustrating the established circuitry of LHA-LepRb neurons
into the mesolimbic dopaminergic system. LHA-LepRb regulates the mesolimbic
dopamine system both directly via projections to the VTA and indirectly via
innervation of local orexin neurons.
1.2.2 Leptin regulates orexin’s neuronal activity. In addition to sending
direct projections to the VTA, LHA LepRb-expressing neurons also innervate local
orexin neurons as shown in Figure 1.2 {(Louis et al. 2010) and our own data
detailed in Chapter 4}. Orexin neurons are exclusively found within the LHA where
they are co-mingled but not co-expressed with LHA LepRb neurons {(Louis et al.
2010, Leinninger et al. 2009) and our data shown in Chapter 2}. Importantly, orexin
neurons regulate various aspects of reward function largely via direct activation of
the VTA-DAàNAc pathway {illustrated in Figure 1.2 (Peyron et al. 1998, Fadel and
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Deutch 2002, Baldo et al. 2003)}. Typically, orexin neurons are activated in
response to low serum glucose levels (Cai et al. 1999, Moriguchi et al. 1999) as
also seen during fasting (Sakurai et al. 1999), and activation of orexin neurons is
strongly correlated with food/reward-seeking behaviors (Harris, Wimmer, and
Aston-Jones 2005). Central administration of the orexin peptide increases the
incentive motivation to work for sucrose pellets, while central (VTA) injections of
orexin receptor antagonists block this effect (Choi et al. 2010). Activation of orexin
neurons is also triggered by environmental cues that predict the arrival of a
palatable food reward; a mechanism thought to enhance food anticipatory and
seeking behaviors (Harris, Wimmer, and Aston-Jones 2005). Thus, the activity of
orexin neurons, and subsequent mesoaccumbal DA response, relies on both
nutritional signals regulating energy balance as well as environmental cues
predictive of food rewards.
As mentioned, leptin is primarily considered a signal of nutritional status, but
it also modulates reward function via inhibition of the mesolimbic DA system. This
effect occurs, partly, via leptin-mediated inhibition of orexin neurons. In
electrophysiological recordings from brain slice preparations, leptin application
reduced the firing frequency of orexin neurons (Yamanaka et al. 2003), and this
was observed by a reduction of excitatory inputs onto orexin neurons (Yamanaka et
al. 2003, Cai et al. 1999, Horvath and Gao 2005). Leptin treatment also attenuates
food/reward-driven behaviors that are associated with the activation of orexin
neurons, as sucrose-seeking behaviors are significantly decreased following a
leptin injection (Figlewicz et al. 2006). Since LHA LepRb neurons innervate local
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orexin neurons, it seems highly likely that leptin action specific to LHA LepRb
neurons would regulate food/reward-motivated behaviors via inhibition of orexin
neurons. However, the precise LepRb population mediating this effect has yet to be
identified.

1.3 CHARACTERIZATION OF CENTRAL GALANIN ACTION
As previously eluded to, the discrete distribution patterns of LepRbexpressing neurons throughout the brain suggest that each LepRb population
contributes to distinct aspect of leptin action. This idea is reinforced by the fact that
LepRb neurons exhibit differential molecular and neurochemical properties based
on their anatomical position within the brain. Specific to the LHA/perifornical area
(PFA) we have identified a novel subpopulation of LepRb neurons that co-express
the neuropeptide galanin, which we refer to as Gal-LepRb neurons. Leptin
mediates anorexigenic action via LepRb; however, central galanin signaling is often
recognized for evoking orexigenic (appetitive) effects. Thus, we aim to understand
how leptin regulates central galanin signaling via Gal-LepRb neurons and
determine how galanin’s effects in this novel LepRb population would translate into
aspects of feeding and body weight regulation.
1.3.1 Galanin introduction. Galanin is a 29 amino acid peptide that is
widely expressed throughout the brain and periphery and functions in various
physiological processes. Centrally, galanin elicits its inhibitory effects both directly
as galanin decreases the spontaneous firing of neurons in the locus coeruleus (LC)
(Seutin et al. 1989) and indirectly as presynaptic galanin action inhibits glutamate
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release in the ARC (Kinney, Emmerson, and Miller 1998). Galanin’s inhibitory
effects are mediated through the activation of any of its three known G-protein
coupled receptors: GalR1, GalR2 and GalR3 (Figure 1.3). Specifically, GalR1 is
widely expressed in the brain and galanin signaling via GalR1 has been recognized
to modulate reward via palatable food selection and opioid-mediated reward
function (Zorrilla et al. 2007, Holmes et al. 2012). GalR1 signals via Gi-pathway to
reduce adenyl cyclase activity and thus induce the subsequent reduction in the
cAMPà protein kinase A (PKA)à cAMP response element binding protein (CREB)
pathway. Since galanin-GalR1signaling decreases CREB phosphorylation, pCREB
can be used as a marker to assess galanin’s involvement in reward circuits (Hawes,
Narasimhaiah, and Picciotto 2006).
1.3.2 The role of galanin in macronutrient selection. Galanin signaling
within the hypothalamus has prominent effects on food intake and fat deposition. In
contrast to the anorexigenic-acting hormone leptin, centrally administered galanin
stimulates feeding (Tachibana et al. 2008). Furthermore, when rodents are allowed
to choose between distinct macronutrients, galanin evokes the preferential intake of
fats over carbohydrates and proteins (Tempel, Leibowitz, and Leibowitz 1988).
Consistently, galanin deficient mice or central injections of galanin receptor
antagonists are shown to reduce fat consumption (Adams et al. 2008, Odorizzi et
al. 2002). A positive feed-forward mechanism is thought to further drive fat intake,
as the consumption of a high fat diet increases hypothalamic galanin gene
expression (Leibowitz et al. 2004).
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Adapted from Hökfelt T, Experienta Supplementum, 2010
Figure 1.3 Signal transduction of galanin’s 3 known G-protein coupled receptors:
GalR1, GalR2, and GalR3
As mentioned, palatable food intake is partly regulated via galanin activation
of GalR1. GalR1-deficient mice decrease their caloric intake when put on a high fat
diet, despite their initial increased consumption in the 3-day acclimation to high fat
(Zorrilla et al. 2007). Interestingly, GalR1 deficient mice show normal feeding
behaviors on a standard chow diet, suggesting a specific role for galanin signaling
via GalR1 in regulating fat intake.
1.3.3 The role of galanin in opioid-mediated reward. Galanin is also
widely recognized for its role in reward and addiction pathways, specifically via
modulation of opioid neurotransmission. Like galanin, opioids are potent
stimulators of food intake and localized NAc injections of µ-opioid receptor agonists
preferentially increases lipid consumption (Zhang, Gosnell, and Kelley 1998).
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Central administration of galanin receptor agonists decreases opiate reward and
attenuates opioid withdrawal symptoms (Zachariou, Parikh, and Picciotto 1999,
Holmes et al. 2012). Consistently, galanin deficient mice experience both increased
reward and withdrawal from opioids (Hawes et al. 2008), which appears to be
largely regulated via GalR1 (Holmes et al. 2012). Galanin binding also seems to be
high within dopaminergic areas of the brain (Hawes and Picciotto 2004), implicating
a possible role for galanin in motivated feeding behaviors.
Previous reports investigating the interaction between leptin and galanin
have been largely inconsistent; claiming leptin may decrease (Sahu 1998b, a) or
increase (Cheung et al. 2001) galanin gene expression, or has no effect on galanin
gene expression at all (Williams et al. 1991). Such discrepancies are due to poor
visualization of galanin- and LepRb-expressing neurons via antibody detection
methods. Therefore, determining their accurate co-expression patterns would be
extremely difficult. Thus far, the role galanin plays in nutrient reward has not been
investigated using novel state of the art technologies such as transgenic or
Cre/LoxP genetic mouse models. To appropriately investigate a potential
interaction between central galanin and leptin signaling, we implement neuronspecific Cre/LoxP technologies to generate genetic mouse lines for: 1). accurate
visualization of galanin and LepRb neurons via green fluorescent protein (GFP)
reporter lines, 2). galanin and LepRb neuronal circuit tracing studies 3). developing
a galanin-specific LepRb Knock Out (KO) mouse line. Here we aimed to establish
the importance of leptin action specific to galanin neurons for modulating energy
balance and potentially properties of nutrient reward.
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CHAPTER 2. LEPTIN RECEPTOR NEURONS IN THE MOUSE
HYPOTHALAMUS ARE COLOCALIZED WITH THE NEUROPEPTIDE
GALANIN AND MEDIATE ANOREXIGENIC LEPTIN ACTION1
2.1 INTRODUCTION
Leptin controls energy homeostasis centrally via neurons that express the
long form leptin receptor (LepRb). Several LepRb populations have been identified
based on their anatomical location, co-expression of neuropeptides or other marker
genes (Balthasar et al. 2004, Coppari et al. 2005, Dhillon et al. 2006, Hayes et al.
2010, Leinninger et al. 2009, van de Wall et al. 2008), which helped to clarify their
commensurate contribution to full leptin function. In fact, most LepRb populations
studied showed a significant, but surprisingly mild, contribution to full leptin function.
However, the majority of LepRb subpopulations have not been studied in detail,
largely due to the lack of specific markers for significant subpopulations of LepRb
neurons.
Galanin is an orexigenic neuropeptide and galanin neurons are found
throughout the brain, but a particularly dense population exists in the dorsomedial
hypothalamus. However, orexigenic galanin action is mediated by the
paraventricular nucleus (PVN), because PVN galanin injections most prominently
increase food intake (Kyrkouli et al. 1990). The literature involving a possible
interaction of galanin and leptin is very inconsistent. Some studies suggest contrary
galanin and leptin action, because genetic deletion of galanin amplifies leptininduced weight loss (Hohmann et al. 2003, Hohmann et al. 2004). This may involve
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  Reprinted with permission of the American Journal of Physiology-Endocrinology
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leptin-mediated regulation of galanin gene expression, even though the
experimental data is scarce and experiments are difficult to compare due to
different experimental approaches, detection methods and anatomical areas
investigated. This may explain the inconsistent results showing that leptin may
decrease (Sahu 1998b, a) or increase (Cheung et al. 2001) galanin gene
expression, or does not effect galanin gene expression at all (Williams et al. 1991).
Likewise, it is unclear if leptin directly or indirectly acts on galanin neurons,
again demonstrated in controversial results showing that LepRb is either rarely
(Cheung et al. 2001) or extensively (Hakansson et al. 1999, Iqbal et al. 2001) colocalized with galanin in the hypothalamus. Both LepRb- and galanin-expressing
neurons cannot be easily visualized immunohistochemically. Galanin is rapidly
transported into neuronal processes, so that immunohistochemical (IHC) staining
for galanin cannot visualize cell bodies, unless animals are treated with colchicine
to prevent vesicular galanin transport into processes (Perez et al. 2001). LepRb is
expressed in low quantity, so that available LepRb specific antibodies are not
sensitive enough to detect LepRb cell bodies, but LepRb-responsive neurons can
be easily and reliably detected by leptin-induced phosphorylation of STAT3 (Faouzi
et al. 2007, Munzberg, Flier, and Bjorbaek 2004, Zhang et al. 2011). However, such
signaling pathways are blocked by colchicine treatment, so that LepRb and galanin
cannot be easily detected together. Thus, in this study we aimed to reinvestigate
the co-expression of galanin and LepRb and to start to evaluate if and how galanin
may mediate physiological leptin action. To do this we used mice with transgenic
green fluorescent protein (GFP) expression from the galanin promoter to
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systematically characterize the existence, anatomical location and chemical nature
of such Gal-LepRb neurons.

2.2 MATERIALS AND METHODS
2.2.1 Mouse strains. To visualize galanin expressing neurons we used male
BAC transgenic mice (FVB background) with green fluorescent protein (GFP)
expression under the control of the galanin promoter {GalTgGFP, Stock Tg(GalEGFP109Gsat, identification number 0163420UCD}, which were obtained from the
Mutant Mouse Regional Resource Center (MMRRC, http://www.mmrrc.org ), a
NCRR-NIH funded strain repository, and were donated to the MMRRC by the
NINDS funded GENSAT BAC transgenic project (http://www.gensat.org ). GalTgGFP
mice and LepRbGFP mice used in this experiment were bred in-house by crossing
FVB wildtype mice with hemizygous GalTgGFP or by crossing double homozygous
LepRbGFP mice, respectively. Male LepRbGFP mice on a mixed background were
used to visualize LepRb neurons and were derived from the colony of Dr. Martin
Myers (University of Michigan, Ann Arbor, MI) and has been described in detail
elsewhere (Leshan et al. 2006). Male C57/B6 mice were obtained from Jackson
Laboratory (Bar Harbor, MA). All animals were group housed at a 12:12h light: dark
cycle with ad libitum access to food and water unless stated otherwise. All animal
breeding and experimental procedures were approved by the Institutional Animal
Care and Use Committee and Pennington Biomedical Research Center.
2.2.2 Peripheral leptin treatment. To identify LepRb neurons via leptininduced pSTAT3 induction, we treated GalTgGFP mice (n=3) or LepRbGFP mice (n=2)
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intraperitoneal (i.p.) with leptin (5 mg/kg body weight) and perfused them 1h later.
The leptin dose and incubation time were used based on earlier studies showing
that leptin-induced pSTAT3 greatly co-localized with LepRb-GFP expressing
neurons (Faouzi et al. 2007, Leinninger et al. 2009, Leshan et al. 2009, Zhang et al.
2011). Leptin was obtained from Dr. Parlow (National Hormone and Peptide
Program, http://www.humc.edu/hormones). For studies investigating leptin-induced
cFos (as a surrogate of neuronal activity) in LepRb neurons, we treated LepRbGFP
mice with PBS or leptin (5 mg/kg, i.p.) and perfused for brain fixation after 3 hours
(n=3-4 per group). Following treatments animals were perfused as described below
in section 2.2.7.
2.2.3 In situ hybridization. To verify correct transgenic galanin-GFP
expression we compared the distribution of GFP expression with the known
distribution of galanin mRNA expression. Galanin in situ hybridization (ISH) data
were used from the Mouse Allen Brain Atlas (Seattle, WA) and were available via
http://www.brain-map.org. Reproduction of ISH images was with permission of the
Allen Institute for Brain Science.
2.2.4 Chronic cannulations for central injections. For central injections
we chronically implanted single cannulas (Plastics One C353, Roanoke, VA) into
the lateral ventricle (-0.3mm caudal, 1mm lateral and 2.1mm ventral to Bregma) or
into the exPFA (-1.8mm caudal, -0.9mm lateral and -4.25mm ventral to Bregma in
GalTgGFP mice and -1.1mm caudal, 0.9mm lateral and 4.75mm ventral to Bregma in
C57B6 mice). GalTgGFP (n=2, for colchicine injection into the lateral ventricle, n=8 for
intra exPFA cannulation) or C57/B6 mice (n=12) were deeply anesthetized with 1-
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3% isofluorane/oxygen and the head was mounted on a stereotaxic frame (M1900
Stereotaxic alignment system, Kopf instruments, Tujunga, CA). An incision was
made to expose the skull and an access hole was drilled to insert the guide
cannula, which was secured in place with Loctite 454 (Fisher, Pittsburgh, PA) and
dental cement before the wound was closed with wound clips. A dummy cannula
was inserted into the guide and analgesia treatment was performed systemically
every 12 hours for 2 days with buprenorphine (10 mg/kg) and once locally to the
incision site with bupivacaine/lidocaine (2.5-12.5 mg/kg). Animals were recovered
for 1 week after surgery before injections were performed.
2.2.5 Colchicine treatment. To allow efficient visualization of neurotensin
(Nts) in GalTgGFP mice (n=2), we injected a single dose of freshly diluted colchicine
(1 µl of 10 µg/µl colchicine in sterile saline; Sigma, St. Louis, MO) into the lateral
ventricle. 24 hours post-colchicine injections mice underwent transcardiac
perfusion with 10% neutral buffered formalin for tissue fixation and brains were
extracted for further processing.
2.2.6 Central leptin treatment and measurement of metabolic
parameters. GalTgGFP mice and wildtype C57/B6 mice with unilateral exPFA
cannulation were habituated to the metabolic chamber for 3 days. After that, mice
were monitored daily for body weight and food intake and continuously for oxygen
consumption, carbon dioxide production and locomotor activity (CLAMS, Columbus
Instruments; Columbus, OH). After 3 days of baseline data collection, mice were
divided into two groups, one group (n=3-6) received a single leptin injection {dose:
20 ng/100 nl sterile phosphate buffered saline (PBS)} and the other group (n=3-6)
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received 100 nl PBS, injections were performed at a rate of 10 nl/60 s to give time
for volume absorption. Leptin doses were used that we found earlier to be sufficient
(20 ng) or insufficient (1 ng) to produce a measureable leptin response after central
intracerebroventricular (i.c.v.) injections (Faouzi et al. 2007). Data collection was
continued for 4 days post-injection. Mice were allowed to recover for 1 week in
home cages after the last day of measurements. The experiment was then
repeated with a lower leptin dose (1 ng/100 nl) and groups were crossed over so
that each mouse received leptin only once during the studies (1 or 20 ng). At the
end of the study, animals were perfused and analyzed for correct cannula
placement, and two mice were removed from the studies due to cannula
misplacement (see arrow in Figure 2.11D).
2.2.7 Perfusion and immunohistochemistry. For perfusions animals were
deeply anesthetized with an overdose of pentobarbital (60 mg/kg) and transcardiac
perfusion with ice cold physiological saline for 30 seconds and ice cold 10% neutral
buffered formalin (Sigma, St. Louis, MO) for 5 minutes. Brains were removed, post
fixed overnight in fixative, transferred to 30% sucrose for 48 hours before
cryosectioning into 4 representative series per brain of 30 µm sections on a sliding
microtome. For immunohistochemistry (IHC) procedures, free-floating tissue
sections were used. Nuclear peptides (cFos or pSTAT3) were stained first and
developed with the diaminobenzidine (DAB) method. Staining with additional
primary antibodies were performed (neuropeptides and GFP) and detected with
fluorescent-labeled secondary antibodies, Alexa568 (neuropeptides) or Alexa488
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(GFP; refer to List of Primary Antibodies on page xi for primary antibody
description).
For nuclear DAB IHC detection of pSTAT3 and cFos, the tissue was
pretreated with 0.3% hydrogen peroxide in methanol for 20 minutes to block
endogenous peroxide, followed by a 10 minute treatment in 0.3% glycine in
phosphate buffered saline (PBS), and an additional 10 minute treatment in 0.03%
sodium dodecyl sulfate in PBS. After that, sections were blocked for 3 hours in 3%
normal donkey serum in PBS/0.25% Triton X-100/0.2% sodium azide. pSTAT3 or
cFos antibodies were added (rabbit anti-pSTAT3, 1:1000 or rabbit anti-cFos, 1:3000
in blocking solution) and incubated overnight at 4C. On the next day, sections were
washed with PBS, incubated with a biotinylated secondary donkey anti-rabbit
antibody for 1 hour (1:1000, in blocking solution without sodium azide). A
biotinylated-horseradish peroxidase (HRP) enzyme is pre-incubated (1 hour) with
free avidin to form the avidin-biotin complex (ABC solution: per 10 mL PBS= 20 µL
avidin solution + 20 µL of biotin solution) and sections are then incubated in the
ABC solution (Vector Laboratories, Burlingame, CA) for 1 hour. Finally, the signal
was developed by 1x DAB solution (Pierce DAB Substrate Kit, ThermoScientific;
Waltham, MA) giving a brown precipitate. Sections were then washed with PBS
and staining with additional primary antibodies was performed (neuropeptides and
GFP) and detected with fluorescent-labeled secondary antibodies, Alexa 568
(neuropeptides), or Alexa 488 (GFP). Sections were mounted onto gelatin-subbed
slides and cover slipped with Pro-Long Anti-fade mounting medium (Invitrogen;
Carlsbad, CA) for further microscopy analysis.
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2.2.8 Antibody characterization. The anti-pSTAT3 antibody stains a single
band of 80kDa molecular weight on Western blots after stimulation with ciliaryneurotrophic-factor (CNTF; manufacturer’s technical information). The specific
detection of leptin-induced pSTAT3 was originally characterized by comparison of
pSTAT3 signal in vehicle versus leptin-stimulated brain sections by Western blots
and IHC (Faouzi et al. 2007, Munzberg, Flier, and Bjorbaek 2004, Munzberg et al.
2003); in both cases leptin robustly increased pSTAT3 signals. Furthermore,
induction of pSTAT3 by leptin was found in an anatomical distribution similar to in
situ hybridization signals for LepRb (Munzberg, Flier, and Bjorbaek 2004, Munzberg
et al. 2003, Faouzi et al. 2007) and conditional deletion of LepRb in steroidogenic
factor 1 (SF1) or proopiomelanocortin (POMC) neurons resulted in SF1 and POMC
specific lack of leptin-induced pSTAT3, respectively (Dhillon et al. 2006, Plum et al.
2006). Specificity of anti-CART and anti-galanin has been tested by omitting the
primary antibody and pre-adsorbing the antibody with the immunogen, which
resulted in all cases in a complete lack of staining for all sections (Dun et al. 2000,
Sherin et al. 1998). Specificity of anti-MCH (melanin concentrating hormone), orexin, -neurotensin and –TH (tyrosine hydroxylase) was verified by analysis of
their typical distribution pattern as reported by others (Aston-Jones, Zhu, and Card
2004, Swanson, Sanchez-Watts, and Watts 2005). Anti-GFP antibodies were
verified by immunohistochemical staining of brains from LepRbGFP reporter mice
compared with control mice that do not express GFP (unpublished data) and by colocalization of LepRbGFP with leptin-induced pSTAT3 {Figure 2.3 and (Zhang et al.
2011)}.
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The anti-cFos antibody recognizes the 55kDa cFos and 62kDa v-Fos
proteins and does not cross-react with the 39kDa Jun protein (manufacturer’s
technical information). Specificity of anti-cFos has been tested by omitting the
primary antibody and pre-adsorbing the antibody with the immunogen, which
resulted in all cases in a complete lack of staining in all sections (Elmquist et al.
1997).
2.2.9 Leptin induced gene expression. For assessment of leptin regulated
gene expression in the exPFA of ob/ob mice (8-10 weeks old) were treated twice
daily with leptin (i.p. 5 mg/kg body weight) or PBS over 3 days (n=6 per group). On
the 3rd day the last injection was given in the morning and tissue was collected 2
hours later. Animals were anesthetized with pentobarbital (60 mg/kg) and
decapitated for rapid brain removal. Brains were sliced in a pre-cooled rodent brain
matrix for mice (Electron Microscopy Sciences, Hatfield, PA) consisting of 1mm,
coronal dividers, and the exPFA and ARC were harvested from a 1mm coronal
brain slice (approximately -1 to -2 mm caudal from Bregma). To obtain consistent
tissue pieces we used the mammillothalamic tracts (mt) as landmarks to cut
horizontal to the 3rd ventricle (defining the dorsal border of the exPFA). Another cut
was made through the mt parallel to the 3rd ventricle (defining the lateral border of
the exPFA) and a 3rd cut was made laterally to remove any remaining
cortex/amygdala structures. No ventral cut was performed, maintaining the natural
ventral base of the exPFA. The ARC piece was collected from the ventral portion of
the remaining midline piece. RNA was isolated with the ToTALLY RNA kit (Ambion,
Carlsbad, CA) and 350 ng RNA was used as template for the generation of cDNA
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(RETROscript kit, Ambion, Carlsbad, CA). For quantitative PCR 10.5 ng template
cDNA was used to determine gene expression using Taqman assays for SOCS3
(Mm00545913_s1), galanin (Mm01236508_m1) and GAPDH (Mm99999915_g1),
the latter served as housekeeping gene. Fold induction of gene expression with
leptin was analyzed with the ΔΔCt method (also known as the comparative Ct
method) as determined by the following equation: ΔΔCt = ΔCt, treatment - ΔCt,
control. Here, the ΔCt treatment is the Ct value for the sample normalized to the
endogenous housekeeping gene (GAPDH) and ΔCt-reference is the Ct value for the
control also normalized to the endogenous housekeeping gene.
2.2.10 Estimates of cell counts. We counted the number of LepRb neurons
that were co-localized with cFos (as a surrogate for stimulated neurons) after PBS
or leptin treatment to evaluate whether leptin would stimulate or inhibit exPFA
LepRb neurons. Immunohistochemical staining for cFos and GFP (LepRbGFP) was
visualized with a fluorescent microscope (Olympus BX51) and images were taken
with a digital camera (Olympus DP30BW) using appropriate filters for fluorophores
or bright-field illumination for DAB stain. Images for cFos and GFP were taken at
identical sites, superimposed, and pseudocolored using Olympus Software and
Adobe Photoshop (Adobe Systems, San Jose, CA). Brightness and contrast were
modified for all images to enhance visibility of nuclear pSTAT3 and cFos staining
for figure preparation and cell counts, however, care was taken that all images
within an experiment were modified with identical settings. For each brain (n=3-4
per group) images from 4 anatomical levels were taken, representing the rostrocaudal extension of the exPFA (from Bregma –1.8 to –2.1 mm, as seen in Figure
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2.5). Because the exPFA consists of 3 anatomically different locations (including
the DMH, perifornical area and lateral hypothalamus) that may respond differently
to stimuli, we subdivided the exPFA into 3 sub-areas for analysis: lateral
hypothalamus (LH), perifornical area (PFA) and the DMH. A vertical line through the
fornix separated the LH and PFA. The DMH and PFA were separated by a vertical
line based on the distribution of DMH LepRb neurons. The total number of
LepRbGFP neurons and cFos/GFP neurons were estimated by cell counts from
digital images. The total number of GFP neurons within anatomical sites was
analyzed to ensure comparison of similar GFP populations among animals. The
number of cFos/GFP neurons was expressed as percentage of the total number of
GFP neurons in the quantified area. The described cell counts are not intended to
provide precise numbers of stimulated GFP neurons. They instead served as
estimates for a mainly stimulatory or inhibitory action of leptin in LepRb neurons.
To evaluate the number and percentage of galanin-GFP/pSTAT3 neurons
in the exPFA compared to the total number of galanin or pSTAT3 neurons, as well
as to identify co-expression of CART with galanin-GFP/pSTAT3 neurons we
counted cells from GalTgGFP mice (n=3) that were treated with 1 hour leptin (leptin
administered 1 hour before perfusion) and every 4th section was stained for
pSTAT3, GFP and CART. For each brain 4 sections containing the exPFA were
used to determine the number of total pSTAT3, total galanin-GFP, galaninGFP/pSTAT3 double labeled neurons and galanin-GFP/pSTAT3/CART triple
labeled neurons within the exPFA. The total number as well as percentage of
galanin-GFP/pSTAT3 neurons based on total pSTAT3 or total galanin-GFP
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neurons was expressed. For CART co-localizations the mean number of
pSTAT3/GFP/CART neurons was expressed as a percentage of total
pSTAT3/GFP neurons in the exPFA.
We further evaluated the extent of co-localization for galanin and neurotensin
neurons in colchicine treated GalTgGFP mice (n=2). While extensive co-localization
was easily visible, we performed cell count estimates from four exPFA sections of a
single brain. The number of total Nts neurons and Nts/GFP neurons in the exPFA
were determined and Nts/GFP neurons were expressed as the percentage of total
exPFA Nts neurons.
For orexin and MCH co-localization we evaluated the co-localization of
pSTAT3/galanin-GFP with orexin and MCH from GalTgGFP mouse brains (n=3).
Because we did not observe any co-localization of pSTAT3 or galanin-GFP with
orexin or MCH we did not perform cell counts and instead report the anatomical
evidence for lack of co-localization with images.
2.2.11 Statistical analysis. Data were analyzed by student’s t-test (two
group comparison) or by one-way repeated measure ANOVA followed by a HolmSidak test for pairwise comparisons. The statistical tests used are specified
accordingly in the figure legends and a significance level of p<0.05 was used in all
tests.
2.3 RESULTS
2.3.1 Verification of GalTgGFP mice. To verify correct anatomical expression
of galanin-GFP in GalTgGFP mice we compared GFP expression to in situ
hybridization of galanin mRNA expression in adult mice (in situ data kindly provided
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by the Allen Brain Institute, Figure 2.1, A-D). Indeed, galanin-mRNA expression
patterns throughout the brain are very similar; this is illustrated in detail for the
hypothalamus (Figure 2.1, A and B) and locus coeruleus (Figure 2.1, C and D).
It is well known that adrenergic neurons in the locus coeruleus are highly coexpressed with galanin (Holets et al. 1988, Melander et al. 1986, Melander,
Staines, and Rokaeus 1986, Olpe and Steinmann 1991). Thus, we further verified
correct expression of galanin-GFP by demonstrating their co-localization with
tyrosine hydroxylase (TH), which we used as a marker for adrenergic neurons in
the locus coeruleus (Figure 2.1, E). We found that every galanin-GFP neuron colocalized with TH.
There are no known markers for galanin-expressing neurons in the exPFA.
Thus instead, we stained brain sections from GalTgGFP mice with anti-galanin to
detect galanin peptide as well as with anti-GFP to detect galanin-GFP expression
(Figure 2.2). The overall expression pattern of galanin and galanin-GFP fibers was
identical, but cell bodies could only be detected with galanin-GFP (Figure 2.2, A-C).
Furthermore, confocal high magnification images convincingly showed that galaninpositive fibers highly co-localized with galanin-GFP (Figure 2.2, D-F) in the PFA.
These data indicate that galanin-GFP expression correctly corresponds with galanin
neuropeptide expression; thus, verifying GalTgGFP mice as a useful tool to study
galanin expressing neurons.
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Figure 2.1 Similar expression patterns of galanin mRNA and galanin-GFP
expression in the hypothalamus and locus coeruleus. A., C.: In situ hybridization
for galanin mRNA expression shows the distribution of galanin neurons in the
hypothalamus (A.) and locus coeruleus (C.) of an adult mouse brain. Images were
kindly provided by the Allen Brain Atlas Institute. B., C.: Immunohistochemical
detection of galanin-GFP in GalTgGFP mice shows strong anatomical similarity to
galanin mRNA expression with many galanin neurons in the hypothalamus (DMH,
PFA and LH) (A. and B.) and the locus coeruleus (C. and D.). E. Double
immunohistochemistry in GalTgGFP mice for galanin-GFP (green) and tyrosine
hydroxylase (TH, red), a marker for adrenergic neurons, confirms the adrenergic
character of galanin-GFP neurons in the locus coeruleus (E.). Note that galaninGFP also visualizes neuronal projections of galanin neurons, which are nicely
visible in the pre-coeruleus that is void of galanin cell bodies.
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Figure 2.2 Co-expression of galanin (peptide) and galanin-GFP in synaptic boutons
of neuronal processes. Double immunohistochemistry in GalTgGFP mice for galaninGFP (green, A. and D.) and galanin peptide (red, B. and E.) shows similar
distribution of neuronal processes in the DMH, PFA and LH (merge, C and F.). High
magnification of the PFA under a confocal microscope (magnification is 63x, D. to
F.) shows a complete overlap of galanin peptide containing synaptic boutons with
galanin-GFP. Note, cell bodies are only visualized with galanin-GFP, but as
expected not with galanin peptide.
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2.3.2 Distribution of galanin-expressing LepRb neurons. The
immunohistochemical detection of LepRb is difficult due to unspecific antibodies or
lack of sensitivity. Leptin activates LepRb via the janus kinase-2/pSTAT3 signaling
pathway, resulting in a robust induction of nuclear pSTAT3 that can be detected by
western blotting as well as immunohistochemistry (Faouzi et al. 2007, Munzberg,
Flier, and Bjorbaek 2004, Munzberg et al. 2003). We used LepRbGFP reporter mice
to demonstrate that LepRb neurons show no pSTAT3 signal when injected with
PBS (Figure 2.3, A), while an i.p. injection with 5 mg/kg leptin for 1h resulted in a
robust induction of nuclear pSTAT3 that highly co-localized with LepRbGFP neurons
(Figure 2.3, B). We further confirmed earlier findings that leptin-induced pSTAT3
co-localizes with about 80% of LepRbGFP neurons {Figure 2.3, C; (Leinninger et al.
2009, Zhang et al. 2011)}, demonstrating that leptin-induced pSTAT3 is highly
representative for LepRb neurons.
Galanin-GFP neurons are densely packed in the DMH, however, surprisingly
only a small subpopulation in the ventral portion of the DMH (vDMH, Figure 2.4, A)
co-expressed leptin-induced pSTAT3, marking LepRb-expressing neurons (galaninGFP/pSTAT3 neurons). The majority of galanin-GFP/pSTAT3 neurons were located
in the perifornical area and lateral hypothalamus, where about 20-44%,
respectively, of all pSTAT3 neurons are co-localized with galanin-GFP (Figure 2.4,
A; Figure 2.5, A; Figure 2.6, B), and 17-28%, respectively, of all galanin-GFP
neurons were co-localized with pSTAT3 (Figure 2.4, A; Figure 2.5, A; Figure 2.6,
B). Another significant population of galanin-GFP/pSTAT3 neurons was found in
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the nucleus of the solitary tract; here about 25% of all pSTAT3 neurons coexpressed galanin (Figure 2.4, B and Figure 2.5, B).
We also carefully examined galanin-GFP neurons in the arcuate nucleus for
potential co-localization with leptin-induced pSTAT3. Even though we found an
occasional co-localization of galanin and pSTAT3, this was negligible compared to
the large number of LepRb neurons found in the ARC (Figure 2.4, C). In Figure 2.5
the rostro-caudal distribution of galanin-GFP/pSTAT3 neurons in the hypothalamus
(Figure 2.5, A) and brainstem (Figure 2.5, B) are shown.

Figure 2.3 Leptin-induced pSTAT3 is a marker for LepRb neurons. LepRbGFP
reporter mice were treated with PBS (A.) or leptin (1 mg/kg body weight, B.) for 1
hour and fixed brain sections were stained for pSTAT3 (red) and GFP (green). C.
Cell counts of double-labeled pSTAT3/LepRbGFP neurons in leptin treated LepRbGFP
mice (n=2) to demonstrate that the majority of leptin-induced pSTAT3 highly
correlates with LepRbGFP expression.
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Figure 2.4 Immunohistochemical detection of Gal-LepRb neurons. Brain sections
from transgenic GalTgGFP reporter mice were stained with double
immunohistochemistry for Galanin-GFP (green) and leptin-induced pSTAT3 (red).
A. Representative image of the exPFA depicting double labeled Gal-LepRb neurons
in the PFA (inset top left), ventral DMH (vDMH, inset top middle) and lack of GalLepRb neurons in the dorsal DMH (dDMH, inset top right). B. Representative image
of the NTS with inset showing several Gal-LepRb neurons. C. Representative
image of the ARC depicting some of the few Gal-LepRb neurons. Scale bars: A.
200 µm; B. and C. 100 µm
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Figure 2.5 Distribution of Gal-LepRb neurons. Rostro-caudal distribution of LepRb
neurons (green, pSTAT3) and Gal-LepRb neurons (red, pSTAT3/galanin-GFP) in
the exPFA (A.) and NTS (B.) relative to Bregma.
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Figure 2.6 Quantification of galanin/pSTAT3 neurons in the exPFA. A. Number of
galanin/pSTAT3 neurons compared to the total galanin or total pSTAT3 neurons in
the exPFA (DMH, PFA, LH) (n=3). B. Percentage of galanin/pSTAT3 neurons
based on total galanin or total pSTAT3 neurons in the exPFA (DMH, PFA, LH)
(n=3).
2.3.3 Neuropeptidergic characterization of galanin-GFP/pSTAT3
neurons. Within the lateral hypothalamus orexin and melanin-concentrating
hormone (MCH)-expressing neurons are two well-characterized neuronal
populations that are both known to regulate energy homeostasis. However, neither
galanin- nor LepRb-expressing neurons were co-localized with orexin (Figure 2.7,
A) or MCH (Figure 2.7, B). Thus, galanin-GFP/pSTAT3 neurons are a distinct
population from orexin and MCH neurons.
Cocaine-and-amphetamine-regulated-transcript (CART)-expressing
neurons are well known in the ARC where they are co-expressed with POMC	
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expressing neurons and are well known as anorexigenic neurons. Another CART
population is found in the lateral hypothalamus and we found that about 56±1.2%
(n=3) of all galanin-GFP/pSTAT3 neurons in the hypothalamus co-express CART
(Figure 2.7, C and Figure 2.8, A).
Leinninger et. al. (2009) showed recently that a large portion of LH LepRb
neurons (about 60% of all LH LepRb neurons) co-express the anorexigenic
neuropeptide neurotensin. Therefore we wanted to investigate if galaninGFP/pSTAT3 neurons would also co-express neurotensin. Indeed, most
identified neurotensin neurons were co-localized with galanin (about 95±3% of
all neurotensin neurons, n=2; Figure 2.7, D and Figure 2.8, B).
Neurotensin/galanin co-localization was restricted to the perifornical area and
LH, suggesting that the neurotensin-LepRb neurons, identified by Leinninger et.
al. (2009) may indeed represent galanin-GFP/pSTAT3 neurons
(galanin/neurotensin-LepRb neurons). However, neurotensin neurons were not
found in the DMH and the few neurotensin neurons in the NTS rarely colocalized with galanin (Figure 2.7, E), suggesting that a subpopulation of
galanin-GFP/pSTAT3 neurons is distinct from neurotensin-LepRb neurons.
Also, many galanin neurons in the LH did not co-localize with
neurotensin. Because we were not able to study co-expression of galanin,
neurotensin and LepRb neurons together (colchicine treatment distorts cell
signaling events like STAT3 phosphorylation), we cannot entirely rule out that
galanin-GFP/neurotensin neurons may specifically not express LepRb.
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Figure 2.7 Gal-LepRb neurons in the exPFA are distinct from orexin and MCH
neurons, but co-express CART and neurotensin. A-C (overviews) and a-c
(magnified): GalTgGFP mice were treated 1h with leptin for detection of leptin receptor
neurons via leptin-induced pSTAT3 (red, nuclear stain). Galanin-GFP is shown in
green (A and B) or blue (C.) and sections were further stained for orexin (blue, A.),
melanin concentrating hormone (blue, MCH, B.) or cocaine-and-amphetamineregulated transcript (green, CART, C.). D (overview) and d (magnified): Colchicine
treated GalTgGFP brain sections were co-stained for galanin (green, GFP) and
neurotensin (red). Scale bar A-D: 200 µm E: Brainstem section of the colchicine
treated GalTgGFP brain co-stained for galanin (green, GFP) and neurotensin (red).
Scale bar E.: 100 µm

	
  
	
  

34

	
  
	
  

35

Figure 2.8 Quantification of CART and neurotensin neurons. A. Cell counts of total
Gal/pSTAT3 neurons in the exPFA and compared to Gal/pSTAT3 neurons that also
co-express the neuropeptide CART (n=3). B. Cell counts of total neurotensin
neurons and neurotensin neurons that also co-express galanin (n=1).
2.3.4 Leptin increases exPFA galanin gene expression. We further tested
if leptin may modulate galanin gene expression specifically in the exPFA. We
compared the exPFA of chow fed ob/ob mice treated with either PBS or leptin over
3 days and indeed found that leptin treatment caused a moderate, but significant
increase in gene expression of galanin (p<0.005, Figure 2.9, A). To confirm correct
leptin stimulation we compared SOCS3 expression in the exPFA and ARC of PBS
and leptin treated mice. Indeed leptin induced SOCS3 expression in the ARC
(p<0.01, Figure 2.9, C) and exPFA, even though in the exPFA data did not reach
significance (p=0.07, Figure 2.9, B).
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Figure 2.9 Leptin induces exPFA galanin gene expression. Relative gene
expression of galanin (A.) and SOCS3 (B and C.) in the exPFA (A. and B.) and
arcuate nucleus (C.) of ob/ob mice treated twice daily with either PBS or leptin
(1mg/kg BW) over 3 days (n=6 per group). *pt-test<0.02
2.3.5 Leptin stimulates exPFA LepRb neurons. Leptin can cause either a
stimulation or inhibition of neuronal activity (Belgardt and Bruning 2010, Cowley et
al. 2001, Munzberg et al. 2007), even though LepRb neurons in the LH have been
mainly associated with stimulatory leptin action (Leinninger et al. 2009). Thus, we
wanted to test if we could recapitulate leptin stimulation of LepRb neurons in all
subdivisions of the exPFA, including the DMH, PFA and LH (Figure 2.10, p<0.03).
We injected LepRbGFP reporter mice with PBS or leptin, perfused brains were
harvested 3 hours later. After IHC staining the number of LepRb neurons that were
co-expressed with cFos as a surrogate for neuronal activity were quantified. As
expected, we found that leptin stimulates LepRb neurons in all subdivisions of the
exPFA (DMH, PFA and LH). Leptin stimulated cFos was found in about 30-35% of
all LepRb neurons (Figure 2.10), thus indicating that leptin may also stimulate
neuronal activity in galanin-GFP/pSTAT3 neurons.
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2.3.6 The exPFA is sufficient for anorexigenic leptin action. Given the
mixed neuropeptide expression of anorexigenic and orexigenic neuropeptides in
galanin-GFP/pSTAT3 neurons, combined with a likely neuronal stimulation of
galanin-GFP/pSTAT3 neurons, we wanted to confirm that leptin action in the
perifornical area (PFA), where the majority of galanin-GFP/pSTAT3 neurons are
found, indeed results in anorexia. Thus, we injected low leptin doses (20 ng and 1
ng) unilaterally into the PFA of GalTgGFP and C57B6 wildtype mice.
We confirmed that PFA leptin is sufficient to decrease body weight and
induce anorexia in GalTgGFP mice (Figure 2.11, A-C) and C57B6 mice (data not
shown). Both doses, 20 ng (data not shown) and 1 ng leptin (Figure 2.11, A-C)
were found effective to reduce body weight (Figure 2.11, A; pANOVA<0.01, pHolm-Sidak
*<0.05), 24h food intake (Figure 2.11, B; pt-test<0.05) as well as respiratory
exchange rate (RER, Figure 2.10, C; pANOVA<0.05, pHolm-Sidak *<0.05), even though
1ng leptin was ineffective in C57B6 mice, likely due to differences in leptin
sensitivity of the background strain (C57B6 versus GalTgGFP mice on an FVB
background).
Cannula placements in C57B6 (blue dots) and GalTgGFP (red dots) mice
are shown schematically in Figure 2.11, D and cases of misplaced cannulas (see
arrow in Figure 2.11, D) were removed from analysis. Figure 2.11, E shows an
example of a cannula track in a GalTgGFP mouse using galanin IHC as landmark
to show correct targeting of the fornix. Thus, we show that leptin action in the
PFA, including galanin-GFP/pSTAT3 neurons, is sufficient to mediate
anorexigenic leptin action in wildtype mice.
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Figure 2.10 Leptin stimulates neuronal activity in exPFA LepRb neurons. LepRbGFP
reporter mice were treated once with leptin (5mg/kg BW, n=3) for 3 hours to allow
time for cFos induction as a surrogate for neuronal activation. The number of cFos
labeled LepRb neurons was estimated by cell counts and reported as percent of
total LepRb neurons (A.). The total number of LepRb (B.) neurons was also
determined to ensure comparison of similar neuronal populations. pt-test<0.03.
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Figure 2.11 Leptin mediates anorexigenic leptin action via the exPFA. A. Body
weight of GalTgGFP mice before and after a single, unilateral injection of either
PBS (n=4) or leptin (1 ng, n=3) into the exPFA. pANOVA<0.01, pHolm-Sidak *<0.05 B.
Food intake of GalTgGFP mice over 24h after receiving a single, unilateral PBS or
leptin (1 ng) injection. pt-test<0.05 C. Respiratory exchange ratio (RER) of
GalTgGFP mice over 24 h after receiving a single, unilateral PBS or leptin (1 ng)
injection; pANOVA<0.05, pHolm-Sidak *<0.05 D. Schematic drawing of cannula
placements in GalTgGFP reporter mice and C57B6 mice. E. Representative
injection site of a GalTgGFP reporter mouse stained for GFP to visualize
anatomical landmarks such as DMH and fornix. Scale bar: 500µm
2.4 DISCUSSION
The aim of this study was to reinvestigate the existence and localization of
LepRb neurons that co-express the neuropeptide galanin, which would characterize
a new subgroup of LepRb neurons and would enable future molecular genetic
studies to identify the importance of such a LepRb subpopulation for physiologic
leptin action.
Here, we show convincing evidence that galanin-GFP/pSTAT3 neurons are
found in two distinct brain locations, one in the hypothalamus and another in the
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brainstem. Leptin-induced pSTAT3 is an excellent marker of LepRb expressing
neurons within the exPFA (DMH, PFA and LH), as shown in Figure 2.3 and earlier
publications (Leinninger et al. 2009, Zhang et al. 2011), thus in the remaining
discussion we will refer to galanin-GFP/pSTAT3 neurons simply as Gal-LepRb
neurons.
Galanin is well known to induce food intake, thus, it is possible that galanin
would not only serve as a genetic marker for a subset of LepRb neurons, but
galanin release from Gal-LepRb neurons could also play a role to mediate
physiological leptin actions on food intake. Surprisingly, our data support that leptin
induces exPFA galanin expression and stimulates neuronal activity in exPFA
LepRb neurons, conflicting with an orexigenic action of galanin in this neuronal
population. We found that Gal-LepRb neurons further co-localize with anorexigenic
neuropeptides like neurotensin or cocaine-and-amphetamine-regulated-transcript
(CART) and intra-exPFA leptin clearly mediated anorexia and weight loss.
2.4.1 Technical considerations. We demonstrate that LepRb neurons coexpress the neuropeptide galanin in two distinct populations found within the
hypothalamus and brainstem. Similar to an earlier double in situ hybridization study
that focused on co-expression within the ARC and DMH, we found no or only
sporadic co-localization in the ARC and only a low percentage of co-localization in
the DMH (Cheung et al. 2001). But our data contradict previous reports that showed
extensive co-localization (60% of all hypothalamic LepRb neurons) in the mouse or
ewe (Hakansson et al. 1999, Iqbal et al. 2001). We hypothesized that these
discrepancies are due to different methods used that may have lacked specificity
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{LepRb IHC, (Hakansson et al. 1999, Iqbal et al. 2001)}. This is also supported by
the fact that extensive co-localization of LepRb with MCH and orexin was reported
(Hakansson et al. 1999, Iqbal et al. 2001). In contrast, our data (using leptininduced pSTAT3) did not support any co-localization of LepRb with MCH or orexin,
which is consistent with earlier published data (Leinninger et al. 2009). Thus, our
data show convincingly that leptin can directly act on galanin neurons in the exPFA
and the nucleus of the solitary tract in the brainstem. Furthermore, we identified
that LepRb and galanin neurons are distinct from orexin and MCH neurons.
2.4.2 LepRb neurons in the brainstem and lateral hypothalamus. LepRb
neurons in the brainstem and lateral hypothalamus (LH) both contribute to the
regulation of energy homeostasis (Leinninger et al. 2009, Hayes et al. 2010).
However, the neuropeptides involved in these leptin actions have not been
completely characterized. Within the LH, a subpopulation of LepRb neurons coexpresses neurotensin (Leinninger et al. 2011). Our data show that exPFA
neurotensin neurons almost entirely co-expressed galanin, even though compared
to the total number of galanin neurons, neurotensin was only found in a small
subset of galanin neurons. Thus, we conclude that the recently described
population of neurotensin-LepRb neurons likely co-expresses galanin, even though
technical limitations prevented us from specifically studying if Gal-LepRb neurons
co-express neurotensin. Importantly, a subset of Gal-LepRb neurons (at least in the
DMH and NTS) clearly does not co-express neurotensin.
Instead, we found that half of all exPFA Gal-LepRb neurons co-expressed
the neuropeptide CART, suggesting a heterogeneous character of Gal-LepRb
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neurons. Surprisingly, we found combined expression of typical anorexigenic
(neurotensin, CART) and orexigenic (galanin) neuropeptides, thus conflicting with
the classic model of orexigenic or anorexigenic neurons (Schwartz et al. 2000).
Within the exPFA, only LH LepRb neurons have been studied in more detail
(Leinninger et al. 2009, Leinninger et al. 2011, Louis et al. 2010), characterized as
the population distal-lateral to the fornix (Harris, Wimmer, and Aston-Jones 2005,
Leinninger et al. 2009), thus excluding neurons in the perifornical area (PFA,
surrounding the fornix) and dorsomedial hypothalamus (DMH, proximal-lateral to
the fornix). LH LepRb neurons are sufficient to regulate body weight and food
intake in leptin-deficient ob/ob mice. Here we show that exPFA leptin administration
is sufficient to decrease body weight and food intake even in wildtype mice. Neither
PFA nor DMH LepRb neurons have been studied in detail for their contribution to
regulate energy homeostasis. Certainly, it will be necessary to further investigate
the physiological importance of these specific Gal-LepRb populations for known
leptin actions, such as food intake, energy expenditure and the rewarding value of
food.
2.4.3 Anorexic leptin action via inhibitory galanin action? To understand
how leptin may regulate body weight and food intake in the exPFA, we tested if
leptin would regulate the co-expressed neuropeptides. Galanin generally increases
food intake (Kyrkouli et al. 1990), suggesting that anorexigenic leptin action should
inhibit galanin expression or block galanin release. Surprisingly, we found that leptin
upregulated galanin gene expression moderately, but significantly, in ob/ob mice.
Furthermore, leptin stimulates neuronal activity in exPFA LepRb neurons,
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suggesting that leptin induces galanin release. It is not plausible that anorexigenic
leptin action requires increased expression and synaptic release of an orexigenic
neuropeptide. Similarly, galanin neurons co-expressed the anorexigenic
neuropeptides neurotensin and CART, again conflicting with an orexigenic galanin
action.
Galanin affects many biological systems from induction of food intake,
reproduction to pain and addiction (Gundlach 2002, Hokfelt et al. 1999,
Merchenthaler 2010, Picciotto 2010). Another prominent feature of galanin is its
inhibitory action (Dong, Tyszkiewicz, and Fong 2006, Poulain, Decrocq, and
Mitchell 2003, Xu, Zheng, and Hokfelt 2005). Interestingly, LH LepRb neurons are
generally GABAergic (Leinninger et al. 2009), thus further supporting the known
inhibitory leptin action on orexin neurons (Louis et al. 2010). Indeed, LH galanin
injections had no orexigenic effects in rats (Kyrkouli et al. 1990). Thus, it is plausible
to speculate that galanin acts as an inhibitory (instead of orexigenic) neuropeptide
in Gal-LepRb neurons and that inhibitory galanin action plays an important role to
mediate anorexigenic leptin action via the exPFA. Consistent with this, orexigenic
galanin action has been attributed to galanin action with the PVN (Kyrkouli et al.
1990, Menendez, Atrens, and Leibowitz 1992, Tempel, Leibowitz, and Leibowitz
1988), while LH LepRb neurons do not project to the PVN, but rather project locally
in the LH and to the VTA (Leinninger et al. 2009).
2.4.4 Leptin regulation of exPFA galanin gene expression. A correlation
of leptin and galanin gene expression has been studied by others with very
inconsistent results, showing that leptin decreased galanin in the hypothalamus of
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wildtype mice (Sahu 1998b, a), had no effect on galanin expression comparing
leptin deficient ob/ob mice and wildtype mice (Williams et al. 1991) or increased
galanin expression specifically in the periventricular region of leptin treated ob/ob
mice (Cheung et al. 2001). The presented results would support leptin induced
gene expression in the exPFA, even though this was not a robust effect. exPFA
galanin neurons may represent a heterogeneous neuronal population, that are coexpressed with several neuropeptides with or without LepRb. Thus, leptin may
regulate galanin expression differentially in subpopulations of galanin neurons.
Furthermore, it needs to be cautioned that mRNA expression may not reflect the
quantity of functional galanin at the synapses or the amount of galanin that is
indeed released into the synaptic cleft. Therefore, changes in mRNA galanin
expression may simply not correlate with changes in behavior.
Leptin robustly stimulates cFos, a marker of neuronal activity, in exPFA
LepRb neurons, suggesting increased neuropeptide release such as galanin.
However, we could not determine if leptin-induced LepRb neurons indeed included
Gal-LepRb neurons, and we cannot rule out that leptin may exclusively stimulate
non-galanin LepRb neurons in the exPFA. Indeed, in the LH as well as other
hypothalamic sites leptin exerts depolarizing and hyperpolarizing effects on
individual LepRb populations (Cowley et al. 2001, Leinninger et al. 2009). Future
studies are necessary to test if galanin indeed contributes to inhibitory leptin actions
{e.g. inhibition of orexin neurons (Louis et al. 2010)} and to demonstrate how this
affects anorexigenic leptin action.
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The perifornical area and lateral hypothalamus are generally involved in
reward behavior (Berthoud and Munzberg 2011) and regulate sleep and arousal via
orexin neurons. Similarly, leptin (Fulton et al. 2006, Gaus et al. 2002, Laposky et al.
2008, Laposky et al. 2006, Leinninger et al. 2009, Lu et al. 2002), galanin (Hawes
et al. 2008, Picciotto 2010), neurotensin (Cape et al. 2000, Geisler et al. 2006,
Hoebel 1985, Jones 2004) and CART (Jaworski et al. 2008, Keating et al. 2010,
Philpot and Smith 2006) have all been associated with the control of reward as well
as arousal behavior. Indeed, neurotensin-LepRb neurons modulate the reward
system via orexin neurons. Even though it is still unknown by which mechanisms
leptin inhibits orexin neurons (Louis et al. 2010). The fact that subpopulations of
exPFA Gal-LepRb neurons also co-express neurotensin or CART suggests that
Gal-LepRb neurons may be involved in the regulation of reward and arousal
possibly via orexin neurons that could be inhibited by leptin induced galanin
release.
In summary, we present clear evidence that LepRb is expressed on galanin
neurons in two distinct locations, one in the hypothalamus and another in the
brainstem. Surprisingly, several Gal-LepRb neurons further co-localized with the
anorexigenic neuropeptides neurotensin or CART. However, intra-exPFA leptin
action clearly demonstrated that leptin mediates anorexia and body weight loss in
the exPFA. Furthermore, leptin induced galanin gene expression in the exPFA of
ob/ob mice, and induced neuronal activity in exPFA LepRb neurons, thus conflicting
with an orexigenic galanin action in this system. Galanin has also been well known
as an inhibitory neuropeptide (Dong, Tyszkiewicz, and Fong 2006, Poulain,
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Decrocq, and Mitchell 2003, Xu, Zheng, and Hokfelt 2005), thus we speculate that
galanin may act alternatively as an inhibitory neuropeptide, rather than an
orexigenic neuropeptide in Gal-LepRb neurons.
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CHAPTER 3. LEPTIN REGULATES NUTRIENT REWARD VIA
GALANIN NEURONS IN THE LATERAL HYPOTHALAMUS
3.1 INTRODUCTION
The rate of obesity is increasing worldwide (Mokdad et al. 2003), and this
effect is likely due to the surplus and accessibility of calorically dense foods in
modern societies. Calorie-rich foods, namely those high in fat and sugar content,
evoke a potent reward response when consumed. With the high availability of such
rewarding foods it seems our current feeding behaviors have shifted from
consuming nutrients solely for homeostatic survival purposes, to now eating foods
based on the pleasure they evoke. Such alterations in nutrient selection behaviors
that govern palatable food intake would indicate a mechanism currently driving the
obesity epidemic.
Leptin is highly implicated in obesity research as leptin signaling through
LepRb exerts its anorexigenic effects via reductions in body fat mass and food
intake. It is now appreciated that anorexic leptin actions are also mediated in part
by leptin’s ability to modulate the rewarding value of food (Fulton et al. 2006).
Reward behavior is regulated by the mesolimbic dopaminergic system, which
consists of dopaminergic (DA) neurons in the ventral tegmental area (VTA) as well
as their projection into the nucleus accumbens (NAc). In this circuit DA release
modulates reward-motivated behaviors in response to a variety of stimuli
(Hernandez and Hoebel 1988, Knutson et al. 2001, Ikemoto and Panksepp 1999,
Nicola et al. 2005). The reward value of nutrients such as sucrose requires
stimulation of midbrain DA neurons and is enhanced by fasting, whereas this effect
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is abolished by central leptin action (Domingos et al. 2011). Indeed, LepRbs are
expressed on midbrain DA neurons and leptin directly inhibits these LepRb-DA
neurons (Hommel et al. 2006). Conversely, leptin deficient ob/ob mice show
reduced NAc DA content and peripheral or intra-LHA leptin rather increases NAc
DA content (Leinninger et al. 2009, Fulton et al. 2006). However, the exact
neuronal circuits involved in stimulating DA release are not entirely clear.
We previously reported on a large population of LepRb neurons in the LHA
(referred to as exPFA in Chapter 2) that co-express the inhibitory acting
neuropeptide galanin (Gal-LepRb neurons). We also showed that LHA galanin
expression was stimulated by leptin (findings reported in Chapter 2). Central
galanin injections selectively increase fat intake, and deficiency in galanin or
galanin-receptor-1 (GalR1) results in decreased dietary fat intake (Zorrilla et al.
2007, Adams et al. 2008). Galanin also regulates reward circuits by inhibition of
mesolimbic DA neurotransmission (Ericson and Ahlenius 1999, Counts et al. 2002),
inhibition of noradrenergic LC neurons (Pieribone et al. 1995, Seutin et al. 1989,
Sevcik, Finta, and Illes 1993) and counteracts withdrawal signs from abusive drugs
(Zachariou et al. 2003). Thus, we hypothesized that Gal-LepRb neurons may play
a critical role in the regulation of nutrient reward and that this could be important for
body weight regulation. To test this, we studied mice with conditional deletion of
LepRb from galanin neurons (Gal-LepRbKO mice). Here we observed that disruption
of leptin signaling in galanin neurons results in differential preferences for sucrose
and Intralipid (fat emulsion solution) and causes increased body weight gain in the
form of a late onset obesity phenotype.

	
  
	
  

49

3.2 MATERIALS AND METHODS
3.2.1 Animals. All mice were bred and housed in a climate-controlled room
(22C) on a 12-hour light/dark cycle with lights on at 7:00A.M. and lights off at 7:00
P.M. Food and water were available ad libitum unless otherwise specified. All
experimental protocols were approved by the Institutional Animal Care and Use
Committee at the Pennington Biomedical Research Center.
Generation of GalCre mice: An IRES-cre sequence was inserted into the 3’
end sequence encoding the murine galanin gene between the STOP codon and
polyadenylation site; and a frt-flanked neo cassette was inserted downstream of the
polyadenylation sites. The construct was electroporated into mouse ES cells
(albino C57B6 background), screening for construct insertion and injection into
C57B6 blastocysts to generate chimeras was performed by the institutional
transgenic core facility. Chimeras were bred to C57B6 mice and coat color
screening was used to determine germline transmission. Correct genotypes were
further confirmed by PCR, initially using long, transgene over-spanning DNA
products to ensure correct insertion into the genome.
Generation of Gal-LepRbKO mice: GalCre mice were further crossed with
LepRbfl/fl mice on the mixed background C57BL/6J, FVB background {(McMinn et
al. 2004) and kindly provided by Dr. Streamson Chua, Albert Einstein College of
Medicine}, which generated Galcre/+; LepRbfl/+ and LepRbfl/+ mice. Final breeding
pairs consisted of Galcre/+; LepRbfl/+ and LepRbfl/fl mice to generate control, wildtype
(WT) LepRbfl/fl mice and Gal-LepRbKO mice Galcre/+; LepRbfl/fl mice or Galcre/cre;
LepRbfl/fl mice.
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Some GalCre experimental animals were further bred on the (B6.129X1Gt(ROSA)26Sortm1(EYFP)Cos/J background (stock#006148)(GalYFP reporter mice) and
compared to transgenic GalTgGFP mice, which we used earlier to identify and
characterize Gal-LepRb neurons in the LHA (as described in Chapter 2). In some
mice the frt-flanked neo cassette was removed from the genome by crossing GalYFP
mice with 129S4/SvJaeSor-Gt(ROSA)26Sortm1(FLP1)Dym/J mice (stock#003946)(Gal(neo)YFP

reporter mice) to prove that reporter expression pattern was not

compromised by the presence of the neo cassette.
Genotyping of experimental animals was performed by PCR assessing
hetero- or homozygous presence of GalCre{(cre forward: CCT CTC CCA AGC GGC
CGG AGA ACC, cre reverse: CCG GCT CCG TTC TTT GGT GGC CCC TTC
GCG,);	
  wt-cre primers: 5’-TCC TGA GAC CAT GTC CAC TG (fwd), 5’-CTG CCA
CTC CTG TGA TCT GA (rev)} and Leprfl (mLepr106: GTC TGA TTT GAT AGA
TGG TCT T, mLepr105: ACA GGC TTG AGA ACA TGA ACA, mLepr65A: AGA
ATG AAA AAG TTG TTT TGG). We used the latter primers also to screen for
potential germline LepRb excision and such animals were excluded from the study.
3.2.2 Metabolic phenotyping. Male Gal-LepRbKO and WT mice (n=11-15)
were weaned into a multi-housing environment at three weeks of age and given
standard rodent chow ad libitum (Laboratory Rodent Diet 5001, Purina). Mice were
individually housed at 4 weeks of age, food intake and body weight was measured
weekly until twelve weeks of age and body weight gain was determined from 4-12
weeks of age. At 12 weeks of age body composition was determined by nuclear
magnetic resonance (NMR; minispec-mq series Bruker Billerica, MA) before mice
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were acclimated to the Comprehensive Laboratory Animal Monitoring System
(CLAMS, Columbus Instruments, Ohio) for 3 days. Energy expenditure and
locomotor activity was monitored continuously over 4 days. In another cohort of
aged 7-9 month old, male Gal-LepRbKO and WT littermates (n=7) body weight was
again evaluated. Differences between groups were statistically analyzed with a
repeated measure 2-way ANOVA or a Student’s t-test.
3.2.3 Microdissection and qPCR. To determine differences in galanin and
galanin receptor expression in the LHA,	
  Gal-LepRbKO and WT mice (n=10-13)
underwent CO2 asphyxiation before decapitation. Brains were rapidly removed and
placed in a pre-cooled rodent brain matrix for mice consisting of 1mm, coronal
dividers (Electron Microscopy Sciences, Hatfield, PA). After initial brain extraction,
the rest of the microdissection procedure was conducted over ice. Ice-cold razor
blades were used to cut 1mm thick brain sections in a rostral to caudal manner.
Visual landmarks such as the mammillothalamic tract (mt), fornix (fx), and the
anterior cinglulate area (aca) were used to strategically dissect the LHA and the
NAc (refer to the schematic in Figure 3.1) from coronal brain slices. LHA tissue
(LHA 1 and LHA 2) pieces were combined and collected in 1.5mL centrifuge tubes,
flash frozen in dry ice, and stored in -80°C until further processed.
RNA extraction, RT-PCR and qPCR procedures were previously described
in Chapter 2. cDNA (10.5ng/reaction) was analyzed in triplicate via quantitative
PCR for GAPDH (housekeeping gene; Mm99999915_g1), Galanin (Mm01236508),
GalR1 (Mm00433515), GalR2 (Mm00726392), and GalR3 (Mm00443617; TaqMan
Universal PCR Master Mix; Applied Biosystems-4304437, Carlsbad, CA) using an
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Applied Biosystems 7500 Real-Time PCR System. Fold induction of gene
expression was calculated using the ΔΔCT method as described in Chapter 2.

NAc

A

B

LHA
(1)

LHA
(1)

LHA
(2)

LHA
(2)

C

LHA
(1)

LHA
(1)

LHA
(2)

LHA
(2)

Figure 3.1 Dissection of the LHA and NAc based on visual anatomical landmarks.
Red lines indicate cuts made for consistent tissue dissection as determined by
visual landmarks. A. Dissection of the NAc (0.98mm from Bregma), using the aca to
make a horizontal cut, followed by two lateral cuts to remove remaining cortex
structures. B-C. Dissection of the LHA rostral (B. -1.22mm from Bregma) to caudal
sections (C. -2.06mm from Bregma). The first cuts were made horizontally through
the mt and the fx to separate LHA (1) and LHA (2). Next, vertical cuts through the fx
separated LHA tissue from other hypothalamic structures (DMH, VMH, and ARC).
Final cuts were made laterally to remove any remaining cortex/amygdala structures.
3.2.4 Test for nutrient preference and reward. To test if WT and GalLepRbKO mice like fat similarly, we offered a fat emulsion (10% Intralipid) for 1 hour
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per day over 10 days in a single bottle to both genotypes to compare their
cumulative fat intake. To assess their preferences for different palatable foods we
further compared their intake of isocaloric solutions of sucrose (25% sucrose) and
Intralipid (10%) in a two-bottle-choice test. Mice were allowed to consume either
solution (water was removed) for 1 hour over 10 days, and bottle positions were
alternated every other day to prevent side preferences. Statistical differences were
analyzed via 3-way repeated-measure ANOVA, followed by a post-hoc analysis to
analyze consumption over time or by 3-way ANOVA to compare absolute intake
after 10 days or during the first 4 days of experiment.
To analyze food-motivated/ reward-seeking behavior, mice were trained to
run down a continually lengthening runway to reach a goal box containing a sweet
treat (fruit loop), which is known as “incentive runway” (Pecina et al. 2003). Briefly,
mice were maintained on a restricted feeding schedule (ad libitum food from 12:004:00 P.M., food removed from 4:00-12:00 P.M.) to enhance training success.
Prompting runway training, mice were allowed overnight access to fruit loops in
their respective home cages to avoid any neophobic responses to the reward. The
incentive runway training procedure was conducted in a staggered schedule,
allowing mice one-day recovery between training sessions to reduce stress. There
were a total of 13 training sessions, with each session consisting of 5 runwayrunning trials (all sessions were conducted between 8:00 A.M. and 12:00 P.M.,
refer to schematic outlined in Figure 3.2). Sessions 1-3 were strictly acclimation
trials, where the mice were granted access to the goal box with the fruit loop treat
present. Runway training began on Session 4 and mice were placed at a starting
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distance of 15 cm from the goal box. With each subsequent session the runway
length was increased in 15 cm increments until reaching a maximal distance of 75
cm. In all sessions, mice were allowed 30 seconds to consume the fruit loop after
completion of the runway task. Video footage of each session was recorded for
slow motion analysis of running speed, number and duration of pauses, and
reversals.

Goal Box
with Fruit
Loop

15cm
30cm
45cm
60cm
75cm
Start
Box

Sessions 1-3: Goal Box acclimation
with Fruit Loop (5min)
Session 4: Runway running
-Distance:15cm
Session 5: Runway running
-Distance: 30cm
Session 6: Runway running
-Distance: 45cm
Session 7: Runway running
-Distance: 60cm
Session 8-13: Runway running
-Distance: 75cm
(5 trials/ session)

Figure 3.2 Incentive runway measures reward-motivated behaviors. For runway
running sessions mice were placed in enclosed start box (at the indicated distance
from the goal box) for 30s. The start box barrier was then removed and mice were
able to enter the runway and proceed to the goal box containing the fruit loop
reward (animals were allowed 30s to consume the reward after each trial).
Completion speed was assessed as the time from which the animal entered the
runway until entering the goal box. Sessions were conducted in a staggered
schedule (1 day training, 1 day recovery), and each session consisted of 5 runway
running trials
3.2.5 Perfusions and immunohistochemistry. GalTgGFP, GalYFP, and Gal(neo)YFP
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administered a single leptin injection (5mg/kg, i.p.) and perfused exactly one our
later. Fixed brains were extracted post-fixed, and cryoprotected as described in
detail in Chapter 2.
Galanin-GFP expression comparison: To visualize Gal-LepRb neurons, brain
sections were immunohistochemically processed as described in Chapter 2 for
leptin-induced pSTAT3 (anti-pSTAT3, 1:1000; DAB) and successively
counterstained for GFP (anti-GFP, 1:1000; fluorescent). Sections were mounted
onto gelatin-subbed slides and cover slipped with Pro-Long Anti-fade mounting
medium (Invitrogen; Carlsbad, CA). Galanin-GFP expression in the LHA and NTS
of transgenic GalTgGFP mice (which was described earlier in Chapter 2) was used to
identify and compare the distribution of Galanin-Cre driven GFP expression in
GalYFP mice and Gal(-neo)YFP mice. Additionally, corresponding LHA and NTS
sections from GalYFP and Gal(-neo)YFP mice were used to identify accurate leptininduced pSTAT3/ GFP co-expression (Gal-LepRb neurons), as those previously
described in transgenic GalTgGFP mice.
Confirmation of proper LepRb deletion in Gal-LepRbKO mice: LepRbexpressing neurons were visualized via immunohistochemical procedures
described in Chapter 2 for DAB labeling of leptin-induced pSTAT3 expression and
further processed as described below.
3.2.6 Estimate of cell counts. Microscopy imaging procedures have been
previously described in Chapter 2. For quantification of leptin-induced pSTAT3 in
the LHA and NTS brains from WT and Gal-LepRbKO mice (n=4-8 per genotype) that
were treated with leptin for 1h were analyzed. For each area 2 sections containing
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leptin-induced pSTAT3 were imaged using the Olympus BX51 bright-field
microscope and Olympus DP30BW digital camera (Olympus; Center Valley,
PA)(LHA=2 sections; NTS=2 sections). pSTAT3 signals were amplified by
appropriate changes in brightness and contrast, making sure that adjustments
remained consistent between sections and animals. The number of pSTAT3
positive cell nuclei was quantified and compared between groups with a Student’s ttest.
3.3 RESULTS
3.3.1 Generation and validation of Gal-LepRbKO mice. In order to
understand the physiological importance of leptin action in galanin neurons we
aimed to delete LepRb selectively from galanin neurons. Thus, we generated mice
that expressed cre-recombinase from the native galanin locus and crossed them
with LepRbfl/fl mice {kindly provided by Dr. Streamson Chua: (McMinn et al. 2004)}
to generate Gal-LepRbKO mice (GalCre/+; LepRbfl/fl or GalCre/Cre; LepRbfl/fl) and WT
littermates (Gal+/+; LepRbfl/fl; mouse construct schematic Figure 3.3, A). For
validation of correct cre-expression in GalCre mice GalYFP mice were generated by
crossbreeding with cre-inducible YFP reporter mice (B6.129X1Gt(ROSA)26Sortm1(EYFP)Cos/J, stock#006148). We compared GFP expressing
neurons in transgenic GalTgGFP mice (Figure 3.3, left panels), which we described
earlier in Chapter 2 to identify and characterize Gal-LepRb neurons in the LHA to
GalYFP mice (middle panels) and Gal(-neo)YFP mice (right panels), where the frtflanked neo cassette was removed from the genome by crossing GalYFP mice with
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mice that express flp-recombinase ubiquitously (129S4/SvJaeSorGt(ROSA)26Sortm1(FLP1)Dym/J, stock#003946).
The distribution of hypothalamic GalGFP neurons was very similar in all
mouse models (Figure 3.3). We also confirmed that galanin neurons correctly
expressed LepRb, by visualizing leptin-induced pSTAT3 with immunohistochemistry
(IHC). As expected, pSTAT3 positive galanin neurons were found in the PFA, LH
and to a lesser extent in the ventral portion of the DMH (Figure 3.3, B) and another
population was found in the NTS (Figure 3.3, C) in GalTgGFP, GalYFP and Gal(-neo)YFP
mice. Galanin neurons with detectable leptin-induced pSTAT3 are further referred
to as Gal-LepRb neurons. All remaining experiments were only performed with
GalYFP mice.
To confirm efficient deletion of LepRb in Gal-LepRbKO mice we compared
leptin-induced pSTAT3 in Gal-LepRbKO and WT littermates. Leptin-induced pSTAT3
was significantly decreased in the LHA and NTS, as seen in IHC images (Figure
3.4, B) as well as by cell counts of pSTAT3 positive neurons (Figure 3.4, C-D; n=45, p<0.01).
3.3.2 Increased body weight gain in Gal-LepRbKO mice. To assess the
metabolic phenotype of Gal-LepRbKO mice we followed their body weight and food
intake over 12 weeks after weaning (4 weeks, n=10-12). Similar to leptin and leptin
receptor deficient mice, Gal-LepRbKO mice show a significantly lower body weight
compared to their WT littermates at 4 weeks of age (Figure 3.4, E; p<0.05). At 12
weeks of age body weights were undistinguishable between both groups (Figure
3.4, E). However, the body weight gain over 8 weeks was significantly increased in
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Gal-LepRbKO mice compared to WT mice (Figure 3.4, F; p<0.05). Consistent with a
slow but accumulating increase in body weight gain we found, in a separate cohort
of aged (7-9 month old) mice, that Gal-LepRbKO mice were indeed significantly
heavier than WT littermates (Figure 3.4, G; n=7-8, p<0.05). However, food intake
(Figure 3.4, H), energy expenditure (Figure 3.4, I) or locomotor activity (Figure 3.4,
J) could not be clearly attributed to these differences in body weight gain.

Figure 3.3 Similar galanin-GFP expression between GalTgGFP, GalYFP and Gal(neo)YFP
mice. A-C. GFP expression in coronal brain sections of GalTgGFP mice (left
panels) GalYFP mice (middle panels) and Gal(-neo)YFP mice where the frt-flanked neo
cassette was removed (right panels). A. Hypothalamic expression GalGFP.
Confirmation of galanin neurons (green) correctly expressing LepRb via
visualization of leptin-induced pSTAT3 (red) in the LHA- B. and in the NTS- C.
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Figure 3.4 Gal-LepRbKO mice experience late-onset obesity. A. Generation of GalLepRbKO mice (GalCre/+; LepRbfl/fl or GalCre/Cre; LepRbfl/fl); mouse construct
schematic. Confirmation of efficient deletion of LepRb in Gal-LepRbKO mice as
visualized B. by leptin-induced pSTAT3 in Gal-LepRbKO (KO) and control (WT)
littermates and quantified via total pSTAT3 cell counts in the LH. C. Metabolic
phenotyping was assessed via weekly body weight- E. and food intake- H.
measurements over 12 weeks after weaning (4 weeks, n=10-12); where GalLepRbKO mice showed a smaller weaning weight compared to WT mice (E.
p<0.05), but no differences of body weight were observed at 12 weeks of age. The
lower weaning weight translated into a significant increase of 8-week body weight
gain in Gal-LepRbKO mice (F. p<0.05), and late-onset obesity was observed in 7-8
month old Gal-LepRbKO mice (G. n=7-8, p<0.05). No differences were observed in
cumulative food intake (H. 4-12 weeks of age), energy expenditure (I. 12 weeks of
age) or locomotor activity (J. 12 weeks of age).
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3.3.3 Decreased LHA galanin signaling is associated with decreased fat
intake. The inhibitory acting neuropeptide galanin has been shown to selectively
modulate the ingestion of fat (Tempel, Leibowitz, and Leibowitz 1988) and we have
shown earlier that leptin increases galanin expression in the LHA. Thus, we tested if
lack of leptin action in Gal-LepRbKO mice similarly regulates gene expression of
galanin or its receptors and if this would modulate fat ingestion. We analyzed
mRNA expression in the LHA of WT and Gal-LepRbKO mice and found a 57%
decrease in galanin expression (Figure 3.5, A; pt-test<0.01) and a 30% decrease in
GalR1 expression (Figure 3.5, B; pt- test<0.05) within the LHA, while gene
expression of all other galanin receptors (GalR2 and GalR3) were unchanged
(Figure 3.5, B)
Thus, we further tested if this affected their fat ingestion. Naïve Gal-LepRbKO
mice and WT littermates had access to a 10% Intralipid (fat emulsion) solution for 1
hour per day over 10 days. It had been reported by others that various
concentrations of Intralipid solution are highly palatable for mice and the amount of
Intralipid ingested correlates with the “liking” of the offered solution (Sclafani 2007).
As expected, both WT and Gal-LepRbKO mice showed increasing Intralipid
consumption over 10 consecutive 1-hour access sessions. However, Gal-LepRbKO
mice consumed significantly less Intralipid solution over the 10 days compared to
WT mice (Figure 3.5, C; n=4-5; pANOVA<0.001; *pHolm-Sidak<0.05-0.001), indicating
that they “liked” the Intralipid solution less than the WT mice.
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Figure 3.5 Altered nutrient reward in Gal-LepRbKO mice. A. LHA galanin mRNA
expression is decreased in Gal-LepRbKO mice (n=10-13, *pt-test<0.01). B. LHA
galanin receptor 1 (GalR1) mRNA expression is decreased in Gal-LepRbKO mice
(n=10-13, *pt-test<0.05). C. Cumulative Intralipid intake is reduced in Gal-LepRbKO
mice during a 1 hour daily access of a single bottle of 10% Intralipid over a 10
period (n=5; pANOVA<0.001; *pHolm-Sidak<0.05-0.001). D. Cumulative sucrose intake is
increased, but Intralipid intake is decreased in Gal-LepRbKO mice during a 1h daily
two-bottle-choice access of isocaloric 10% Intralipid and 25% sucrose solutions
(both 1 kcal/ml) over a 10 period (n=5-7; pANOVA<0.0001; *pHolm-Sidak<0.05-0.001). E.
Comparison of total sucrose and Intralipid intake over 10 days shows a clear
preference of sucrose over Intralipid in Gal-LepRbKO mice, while WT mice did not
show preference for either solution (n=5-7, pANOVA<0.001; * pHolm-Sidak <0.01). F.
Daily intake of sucrose and Intralipid during the first 4 days shows that sucrose
preference is prevalent on day 1 in naïve Gal-LepRbKO mice (pANOVA<0.05; * pHolmSidak
<0.02).
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Next we wanted to test if this behavior was selective for fat or if other
palatable nutrients like sucrose were also less “liked.” In another cohort of naïve
mice (n=6-9) we gave 1-hour daily access to a choice of isocaloric (1 kcal/ml)
solutions of 25% sucrose and 10% Intralipid over 10 consecutive days. Again, GalLepRbKO mice consumed less Intralipid compared to WT mice, but in striking
contrast Gal-LepRbKO mice consumed more of the isocaloric sucrose solution
compared to WT animals (Figure 3.5, D; n=6-9; pANOVA<0.0001; *pHolm-Sidak<0.050.001). While WT mice ingested equal amounts of Intralipid and sucrose solutions
and thus had no preference for either of the solutions, Gal-LepRbKO showed a
robust and significant preference for sucrose over lipids (Figure 3.5, E; n=6-9, *pttest

<0.05). Therefore, deficiency of LepRb in galanin neurons differentially

modulates the preference for sucrose and lipids. Importantly, the robust sucrose
preference in Gal-LepRbKO mice was present from the first day of exposure to the
solutions (Figure 3.5, F; pANOVA<0.05; * pHolm-Sidak <0.02) demonstrating that this
nutrient selection is not due to a learned behavior.
3.3.4 Gal-LepRbKO mice work more for sugar rewards. We further wanted
to evaluate if the increased sucrose preference observed in Gal-LepRbKO mice
would also affect their motivation to work for a sucrose food reward; which has
been also termed “wanting” (Berridge, Robinson, and Aldridge 2009). The incentive
runway has been successfully used in mice to evaluate their motivation to work for
food rewards (Pecina et al. 2003) and is particularly useful in mice due to the
simplicity of the learning task. Mice were trained to run a straight path with
increasing runway length (up to 75 cm) to obtain a visible food reward (fruit loop).

	
  
	
  

63

Various aspects of runway performance were analyzed to compare food-motivated
behaviors between Gal-LepRbKO and WT mice respectively.
Indeed, we found that Gal-LepRbKO mice showed an increased motivation to
work for a sugary treat, which was observed as an increased completion speed to
obtain the food reward (Figure 3.6, A; n=4; pANOVA<0.05; *pHolm-Sidak<0.05-0.02).
Further analysis revealed that Gal-LepRbKO mice had more incidences of direct,
undistracted runs, while WT mice spend significantly more time with distractions
such as pauses, falters and reversals (Figure 3.6, B and C; n=4; pANOVA<0.05; pHolmSidak

<*0.03, #=0.06; pt-test<0.03, respectively). In addition, Gal-LepRbKO mice also ran

faster to obtain the sugary treat compared to their WT littermates (Figure 3.6, D and
E; n=4; pANOVA<0.03; pHolm-Sidak<*0.03, **<0.02, #=0.08; pt-test<0.03, respectively).
3.4 DISCUSSION
Our data demonstrate that LHA leptin action - via galanin neurons – indeed
robustly regulates nutrient reward. Dysregulation of this system, by deletion of
LepRb from galanin neurons, enhances body weight gain and causes late onset
obesity; strongly suggesting that nutrient reward behavior drives body weight gain.
The concept that galanin controls macronutrient selection has been first introduced
by Leibowitz and colleagues, where they found that central galanin injections
selectively increases fat intake, while carbohydrate intake remained unchanged
(Tempel, Leibowitz, and Leibowitz 1988). More recently, galanin’s effect on fat
intake was further supported in galanin deficient mice, which showed a decreased
ingestion of a high fat diet (Adams et al. 2008).

	
  
	
  

64

Figure 3.6 Gal-LepRbKO mice work more for sugar rewards. In the incentive runway
WT and Gal-LepRbKO mice (n=4 each genotype) were tested for their completion
speed (cm/sec= runway length [cm] /time from leaving start box till entering goal
box [sec]) (A.; pANOVA<0.05; *pHolm-Sidak<0.05-0.01).), the number of direct runs (in
contrast to distracted runs) (B., C.; pANOVA<0.05; pHolm-Sidak<*0.03, #=0.06; pttest
<0.03, respectively) and running speed (mean completion speed from all direct
runs)(D., E.; pANOVA<0.03; pHolm-Sidak<*0.03, **<0.02, #=0.08; pt-test<0.03,
respectively). Each session consisted of 5 trials and sessions that were held every
other day.
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Similarly, GalR1 deficient mice show a decreased ingestion of high fat diet, even
though their short-term consumption was initially increased (Zorrilla et al. 2007). In
line with this, our data demonstrate that reduced galanin and GalR1 mRNA
expression in the LHA is associated with decreased fat (10% Intralipid)
consumption, supporting the idea that galanin action in the LHA via GalR1
importantly controls fat ingestion.
On the contrary, we observed that Gal-LepRbKO mice exhibit a robust
preference for sucrose over Intralipid, and even consumed significantly more than
their WT littermates. Leptin deficiency in humans and rodents dramatically
increases the rewarding value of all foods; which mimics the strong effect of fasting
to enhance the rewarding value of food (Myers, Cowley, and Munzberg 2008).
Reward is strongly influenced by midbrain dopamine (DA) neurons and optogenetic
stimulation of DA neurons paired with water intake is strongly preferred over water
without DA neuronal stimulation. However, DA stimulation alone is not able to
override preferences for sucrose solutions (Domingos et al. 2011). This nicely
demonstrates the importance of the DA system for reward, while pointing out that
food rewards such as sucrose require additional regulatory circuits. Sucrose
consumption stimulates DA neurons and metabolic states can either enhance or
abolish DA responses. Thus, fasting enhances sucrose preference over non-caloric
sweeteners, while leptin abolishes this effect.
Our data demonstrate that the robust sucrose preference further translates
into enhanced work for a sweet treat. Gal-LepRbKO mice perform the incentive
runway with increased running and completion speed, and show fewer distractions
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during the task performance. Leptin action in the LHA regulates the mesolimbic DA
system by direct LepRb projections to the VTA (Leinninger et al. 2009) as well as
innervation of orexin neurons (Louis et al. 2010). Moreover, orexin neurons also
innervate the VTA to regulate DA neurons (Korotkova et al. 2003). Indeed,
peripheral leptin injections and intra-LHA leptin increases DA content in the NAc of
ob/ob mice (Fulton et al. 2006, Leinninger et al. 2009). Similarly, orexin action in the
VTA is known to stimulate DA release. However, leptin inhibits orexin neurons,
which should decrease DA release in the NAc. Thus, determining the distinct circuit
by which Gal-LepRb neurons mediate nutrient reward (either via projections to the
VTA, orexin neurons etc.) may resolve some of these discrepancies encountered
when LepRb function is generalized to the entire LHA-LepRb population.
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CHAPTER 4: DEFINING GAL-LEPRB NEURONAL CIRCUIT:
POTENTIAL SITES OF ACTION
4.1 INTRODUCTION
The lateral hypothalamus area (LHA) is a brain region well recognized for its
role in reward function. Particularly, activation of LHA orexin neurons enhances
reward-motivated behaviors, which is largely accomplished via orexin-induced
stimulation of mesoaccumbal DA release. Palatable foods, high in sugar and fat, are
perceived to be highly rewarding and generally evoke an increased motivational
state to obtain them. And orexin mediates these reward responses as central orexin
injections increase sucrose intake, while genetic or pharmacological blockade of
orexin signaling decreases the rewarding value and intake of sucrose (Cason et al.
2010). Moreover, the activity of orexin neurons is highly correlated with sucrose
seeking behaviors (Harris, Wimmer, and Aston-Jones 2005). Thus, the pathway
responsible for negatively regulating orexin’s activity seems to be a crucial
component in aspects of reward-based feeding and the development of obesity.
The anorexigenic hormone leptin is a likely candidate for opposing orexin’s
effects, as leptin treatment decreases the rewarding value of sucrose and attenuates
sucrose seeking behaviors (Figlewicz et al. 2006, Figlewicz et al. 2001). Moreover,
leptin has been shown to inhibit the activity of orexin neurons, but how this is
accomplished has not been determined. We do know that leptin is not capable of
directly inhibiting orexin neurons, as we confirmed that LHA LepRb neurons are not
co-expressed with orexin neurons {(Louis et al. 2010, Leinninger et al. 2009) and our
data shown in Chapter 2}. LHA LepRb neurons were observed to innervate orexin
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neurons (Leinninger et al. 2011, Louis et al. 2010), suggesting that leptin may
indirectly inhibit orexin neurons to regulate nutrient reward. Importantly our data
shows that leptin modulates the reward value of nutrients via LHA Gal-LepRb
neurons. We observed that mice exhibiting targeted LepRb deletion exclusively in
galanin neurons (which we refer to as Gal-LepRbKO mice) exhibit a robust
preference for sucrose over lipids. Interestingly, Gal-LepRbKO mice demonstrated
enhanced food-motivated behaviors for a sugary treat, indicative of increased orexin
activity.
In order to determine the precise pathway by which leptin signaling in GalLepRb neurons modulates nutrient reward, we employed a cell-specific viral tracing
method to study anterogradely-labeled neural projection sites specific to either
galanin and LepRb neurons in the LHA. Here we show that Gal-LepRb neurons do,
in fact, innervate local orexin neurons. In line our hypothesis that Gal-LepRb
neurons mediate leptin’s inhibitory influence over orexin neurons, the absence of
leptin signaling in galanin neurons (Gal-LepRbKO mice) translates into increased
activation of orexin neurons. Interestingly, Gal-LepRb neurons do not project to the
VTA as previously reported for LHA-LepRb neurons, however, they were found to
innervate the noradrenergic locus coeruleus (LC); a nucleus that had not been
associated with leptin action. Importantly, our data demonstrates that Gal-LepRb
neurons are a distinct LHA LepRb population that modulates the reward value of
nutrients by eliciting an inhibitory tone onto orexin neurons.
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4.2 MATERIALS AND METHODS
4.2.1 Animals. All mice were bred and housed in a climate-controlled room
(22C) on a 12-hour light/dark cycle with lights on at 7:00A.M. and lights off at 7:00
P.M. Food and water were available ad libitum unless otherwise specified. All
experimental protocols were approved by the Institutional Animal Care and Use
Committee at the Pennington Biomedical Research Center. GalCre and LepRbCre
mice (described in Chapter 2 and 3) were used for cre-driven/cell-specific
expression of anterograde adeno-viral tracing experiments to investigate projection
sites of Gal-LepRb neurons. GalYFP mice (described in Chapter 3) were used to
identify the presence of retrogradely labeled Gal-LepRb neurons from the LC (to
confirm adenoviral anterograde findings). Finally, a cohort of Gal-LepRbKO mice
and their WT littermates (described in Chapter 3) were used to assess potential
differences in orexin gene expression and neuronal activity.
4.2.2 Acute tracing studies. Adenoviral constructs: To define anterograde
projections from galanin- and LepRb-expressing neurons in the LHA, we employed
the use of molecular tracers with the cre-inducible system (for galanin- and LepRbspecificity) and adenoviral stereotaxic injection (for anatomic specificity) using two
adenoviral vectors, Ad-iz/EGFPf and Ad-iN/WED. For the generation of AdiZ/EGFPf, the floxed β-geo cassette from pCALL was excised and inserted
upstream of the MCS from pShuttleCMV (He et al. 1998) to generate pShuttle-iZ.
The coding sequence of EGFP from pEGFP (Invitrogen) was amplified with the
addition of sequences encoding a COOH-terminal farnesylation by standard PCR
and subcloned into the MCS of pShuttle-iZ to generate pShuttle- iZ/EGFPf, which
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was purified, linearized and utilized to generate the Ad-iZ/EGFPf adenovirus as
previously described (Leshan et al. 2009, Leinninger et al. 2009). Ad-iZ/EGFPf
results in cre-inducible expression of farnesylated EGFP to mark cell bodies and
processes of cre-expressing neurons, while the viral injection spread can be
monitored by β-galactosidase (β-gal) expression in non-cre expressing neurons.
For the generation of the Ad-iN/WED construct, the β-gal-encoding region of the βgeo fusion was deleted in pShuttle/iZ. Thus, generating pShuttle/iN, thereby
decreasing the size of the construct to promote proper viral packaging with larger
inserts. The coding region of WGA along with an IRES element and the coding
sequence for farnesylated DsRed was then subcloned into the MCS of pShuttle/iN
vector to generate pShuttle-iN/WED. Vector DNA was purified, linearized and
utilized to generate the cre-inducible WGA adenoviral vector (Ad-iN/WED). Credependent WGA expression from Ad-iN/WED was verified in vitro by
immunohistochemical staining for WGA in infected HEK293 cells transfected with a
vector encoding cre recombinase as determine previously (Louis et al. 2010). AdiN/WED results in cre-inducible expression of DsRed and wheat germ agglutinin
(WGA). WGA is further anterogradely and transsynaptically transported into second
order neurons, while DsRed remains in first order cre-expressing neurons.
For surgical procedures of acute central injections mice were deeply
anesthetized with 1-3% isofluorane/oxygen and the head was mounted on a
stereotaxic frame (M1900 Stereotaxic alignment system, Kopf instruments,
Tujunga, CA). The surgical area was prepared by shaving and sterilizing the scalp
of the mouse with 70% ethanol and nolvassan. Ophthalmic ointment was next
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applied to the animalʼs eyes to provide lubrication throughout the surgical
procedure. Starting slightly behind the eyes, a midline sagittal incision about 2-3 cm
long was made to expose the skull. Hydrogen peroxide was rubbed directly onto the
skull to remove connective tissue and provide a means to adequately visualize and
define Bregma. Bregma was then used as a reference point to determine the
injection location for the stereotaxic coordinates of the LHA (X -0.9mm, Y -1.3mm, Z
-5.2mm from Bregma) in GalCre and LepRbCre mice, or the LC (X -0.8, Y -5.4, Z 3.7mm from Bregma) in GalYFP mice. An access hole was drilled to insert the guide
cannula. A stainless steel guide cannula with dummy (Plastics One, Roanoke, VA)
was lowered to the appropriate depth, and the injector was loaded with the
respective tracing agent using a 0.5ul Hamilton syringe (Hamilton, Reno, NV). The
filled injector was then inserted into the guide cannula and tracers were infused into
the respective brain areas at a rate of 10nl/20s.
For galanin and LepRb adenoviral anterograde tracing experiments, GalCre
and LepRbCre mice received a LHA-targeted injection of either the Ad-iZ/EGFPf or
Ad-iN/WED adenovirus (250-350nl, 2-6x1012 PFU/ml). After the infusion was
complete, the injector was removed, the hole filled with bone wax and skin was
closed with wound clips. Mice were subcutaneously administered the analgesic,
Carprofen (10 mg/kg: two injections within 24 hours of surgery), and administered
an injection localized to the incision of Buvidiocaine/Lidocaine mixture (2.5 mg/kg).
Mice were allowed to recover on a heating pad and then single-housed in a
biohazard containment room. After 7-10 days incubation time, mice were perfused,
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fixed brains were extracted, cryoprotected (as described in Chapter 2) and
processed for immunohistochemical analysis as described.
For injection of the non-specific retrograde tracer (FG), the cannula was
inserted into the LC (based on above coordinates) of GalYFP mice and 10nl of a
2%FG solution was injected over 20 seconds. The injector was then removed, the
hole filled with bone wax and skin was closed with wound clips. Mice were
subcutaneously administered the analgesic, Carprofen (10 mg/kg: two injections
within 24 hours of surgery), and administered an injection, localized to the incision,
of Buvidiocaine/Lidocaine mixture (2.5 mg/kg). Mice were allowed to recover on a
heating pad and then single-housed in clean cages. 3-5 days post-injection,
animals were administered a single i.p. leptin injection (as described below) and
perfused exactly 1 hour later. Fixed brains were extracted, cryoprotected (as
described in Chapter 2) and processed for immunohistochemical analysis.
4.2.3 Immunohistochemistry. Refer to page xi for detailed primary antibody
information, and Chapter 2 for DAB and fluorescent immunohistochemical detection
methods. For Ad-iZ/EGFPf axonal tracing experiments, detection of cre-inducible
fluorescent expression of the farnesylated enhanced green fluorescent protein
(EGFPf; detected via anti-GFP antibody 1:1000) was used for visualization of
anterogradely labeled axon fibers from LHA galanin and LepRb neurons. The
extent of viral spread in the LHA was immunohistochemically detected via non-cre
specific β-gal expression (Ad-iZ/EGFPf; anti- β-gal, 1:1000).
For Ad-iN/WED neuronal tracing experiments, detection of cre-inducible
fluorescent expression of DsRed (anti-DsRed, 1:1000) was used for visualization of
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primary (cre-expressing) galanin and LepRb neurons, whereas fluorescent
detection of WGA (detected via anti-GFP antibody, 1:1000) allowed the
visualization of both primary and second order (synaptically coupled) neurons from
LHA galanin and LepRb neurons. Further, we determined that LHA galanin neurons
innervate the adrenergic neurons of the LC via neuronal co-expression of galaninderived WGA and tyrosine hydroxylase (anti-TH, 1:1000) within the LC.
Leptin-induced STAT3 phosphorylation: Detection of leptin receptors was
visualized via phosphorylation of the downstream leptin signaling transcription
factor STAT3. To assess if Gal-LepRb neurons, specifically, innervate the LC,
GalYFP mice were injected with the retrograde tracer FG targeted to the LC as
described above. 3-5 days following, mice were injected with 5-mg/kg dose of leptin
(i.p.). Precisely 1 hour after leptin treatment, animals were perfused for brain
fixation. GalYFP mice were confirmed for accurate LC-targeted FG injections (n=2)
via fluorescent FG (anti-FG, 1:1000) expression in the LC. In the LHA,
immunohistochemical detection of triple labeled neurons positive for leptin-induced
pSTAT3 (anti-pSTAT3, 1:1000; detected via DAB), FG (anti-FG, 1:1000;
fluorescently labeled) and GFP (anti-GFP, 1:1000; fluorescently labeled) confirmed
this projection.
To assess differences in baseline activation of orexin neurons in GalLepRbKO and WT mice, brain sections were co-stained for orexin-A (anti-orexin,
1:1000; fluorescently detected) and nuclear cFos (anti-cFos, 1:3000; DAB
detection). Neurons co-expressing cFos and orexin are indicative of an activated
orexin neuron. Sections were mounted onto gelatin-subbed slides and cover
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slipped with Pro-Long Anti-fade mounting medium (Invitrogen; Carlsbad, CA) for
further microscopy analysis described below.
4.2.4 Estimate of cell counts. Microscopy procedures have been previously
described in Chapter 2. For quantification of baseline activity of orexin neurons,
brain sections of WT and Gal-LepRbKO mice (n=5) were analyzed for cFos/orexin
co-expression. Four sections containing the entire population of LHA orexin
neurons were identified for each animal and organized anatomically in a rostral to
caudal manner. The total number of orexin neurons and the number of cFos
expressing orexin neurons was manually counted as described in Chapter 2.
Differences between groups were evaluated with a 2-way ANOVA and posthoc-test.
4.2.5 Microdissection and qPCR. Microdissection procedures have been
described in Chapter 3. For Gal-LepRbKO and WT mice, the mt and fornix were
used for visual landmarks to strategically dissect the LHA (Figure 3.1, B-C). LHA
tissue pieces were combined and collected in 1.5mL centrifuge tubes, flash frozen
in dry ice, and stored in -80°C until further processed.
RNA extraction, RT-PCR and qPCR procedures are detailed in Chapter 2.
cDNA (10.5ng/reaction) was analyzed in triplicate via quantitative PCR for GAPDH
(housekeeping gene; Mm99999915_g1), orexin (Mm04210469_m1),
OX1(Mm01185776_m1), OX2 (Mm01179312_m1); TaqMan Universal PCR Master
Mix; Applied Biosystems-4304437, Carlsbad, CA) using an Applied Biosystems
7500 Real-Time PCR System. Fold induction of gene expression was calculated
using the ΔΔCT method as described in Chapter 2.
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4.3 RESULTS
4.3.1 Gal-LepRb neurons innervate orexin neurons and the LC. To
understand how Gal-LepRb neurons may regulate the observed effects on natural
reward behavior, we aimed to identify the anatomical sites and neurons that were
innervated by both galanin and LepRb neurons from the LHA.
We first injected the adenoviral construct Ad-iZ/EGFPf into the LHA of
LepRbCre or GalCre mice, which resulted in a cre-specific expression of a
farnesylated enhanced green fluorescent protein (EGFPf) and a non-cre dependent
β-galactosidase expression from all adenovirus infected cells (Figure 4.1, A-G). The
farnesylation anchors EGFPf to the cell membrane, which enhances the
visualization of thin axonal processes, the β-galactosidase expression, is used to
track the spread of overall virally infected cells. In a second step, we injected
another adenoviral construct, Ad-iN/WED, that resulted in the cre-dependent
expression of wheat germ agglutinin (WGA) and the fluorescent protein DsRed.
WGA can be transported anterogradely and transsynaptically into 2nd order
neurons, while DsRed is restricted to 1st order neurons (here LepRb or galanin
neurons; Figure 4.1, G-L).
Correctly targeted Ad-iZ/EGFPf injection into the LHA of LepRbCre (Figure
4.1, A) or GalCre (Figure 4.1, D) mice was immunohistochemically visualized by
staining for EGFPf (green) and β-galactosidase (red). EGFPf positive cell bodies
represent LepRb or galanin neurons and many fibers are seen from LepRb and
galanin neurons projecting locally within the LHA (Figure 4.1, A and D,
respectively). Similarly, Ad-iN/WED injection into the LHA of LepRbCre or GalCre
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mice, respectively, results in WGA labeling within the LHA, where 1st order neurons
are identified by WGA and DsRed expression (= yellow neurons) and many 2nd
order neurons that are only positive for WGA (= green neurons) (Figure 4.1, G and
J). Thus, Gal-LepRb neurons intensely innervate local LHA neurons.
We further confirmed that LHA LepRb neurons strongly innervate the VTA
(Figure 4.1, B and H) as had been reported earlier (Leinninger et al. 2011, Louis et
al. 2010). In contrast, we rarely found projections or second order labeled neurons
to the VTA from LHA galanin neurons (Figure 4.1, E and K), suggesting that GalLepRb neurons are unlikely to substantially innervate the VTA.
Instead we found that both – LHA LepRb and galanin neurons - strongly
innervated the LC (Figure 4.1, C and F), a site that had not yet been associated
with leptin function. With Ad-iN/WED we found many 2nd order neurons labeled
from LHA galanin neurons (Figure 4.1, L), and we also found an occasional 2nd
order labeling from LHA LepRb neurons (Figure 4.1, I), however, 2nd order
tracing from LHA LepRb neurons was not observed in all cases of injected
animals. Thus, we further injected the retrograde tracer fluorogold (FG) into the
LC of GalYFP mice, and analyzed the brains for the existence of leptin-induced
pSTAT3 neurons co-localized with GalGFP and retrogradely labeled with FG from
the LC (=FG/pSTAT3/GalGFP positive; Figure 4.2). Galanin is well known to be
co-expressed in the majority of LC neurons (Moore and Gustafson 1989) so that
the GalGFP signal served as a great visual outline for the LC and to verify the
accuracy of FG injections (Figure 4.2, A).
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Figure 4.1	
  Gal-LepRb neurons project to the LC, but not the VTA. A. Injection of AdiZ/EGFPf into the LHA of LepRbCre mice shows the spread of infected neurons in
red (β-galactosidase expression). Cre-recombination removes β-galactosidase
expression and induces EGFPf expression (green, representing LepRb neurons).
LHA LepRb neurons project into the VTA (B.) and LC (C.). D. Injection of AdiZ/EGFPf into the LHA of GalCre mice, again with spread of infected neurons in red
(β-galactosidase expression) and neurons with cre-expression in green (EGFPf).
LHA Gal neurons do not project into the VTA (E.), but strongly innervate the LC
(F.). G. Injection of Ad-iN/WED into the LHA of LepRbCre mice (n=7) shows infected
first order neurons by co-expression of cre-inducible DsRed (red) and wheat germ
agglutinin (WGA, green)(yellow labeling). The anterograde and transsynpatic tracer
WGA is further transported into second order neurons indicated by single WGA
labeling (green) within the LHA (G.), VTA (H.) and LC (I., only observed in one
animal). J. Injection of Ad-iN/WED into the LHA of GalCre mice (n=6) shows local
first order neurons (yellow) and second order neurons (green) are found in the LHA
(J.) and LC (L.), but not the VTA (K.).
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Indeed, we found many triple labeled FG/pSTAT3/GalGFP neurons surrounding the
fornix (Figure 4.2, B) supporting the projection of Gal-LepRb neurons to the LC.
Neurons in the LC are the major source of central norepinephrine and express
tyrosine hydroxylase (TH). Thus, we further confirmed that galanin-derived WGA
labeled LC neurons are indeed co-localized with TH (Figure 4.3, C).
LepRb neurons in the LHA innervate local orexin neurons (Louis et al. 2010),
thus, we further tested if the WGA labeled 2nd order neurons from LHA LepRb or
galanin neurons might in fact be orexin neurons. Indeed, we found that many WGA
labeled from LHA LepRb and galanin neurons were co-stained with orexin (Figure
4.3, A and B, respectively). Importantly, we showed earlier that neither LepRb nor
galanin neurons are co-localized with orexin (data shown in Chapter 2)
demonstrating that Gal-LepRb neurons innervate orexin neurons.

A.

B.

Figure 4.2 Gal-LepRb neurons innervate the LC. GalYFP mice were injected the
retrograde tracer fluorogold (FG, red) into the LC (A), and within the LHA brains
were analyzed for the existence of leptin-induced pSTAT3 (red) neurons colocalized with GalGFP (blue) and retrogradely labeled with FG (green) from the
LC (B).
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4.3.2 Galanin mediated inhibition of orexin neurons. LHA galanin and
GaR1 expression was decreased in Gal-LepRbKO mice (Chapter 3) and galanin is
known for its potent inhibitory action in many neuronal systems, including the
hypothalamus (Dong, Tyszkiewicz, and Fong 2006). Thus, if galanin would be
significantly involved to mediate inhibitory leptin action onto orexin neurons, we
predicted that Gal-LepRbKO mice would show increased activation of orexin
neurons. To test this we analyzed the brains of Gal-LepRbKO mice and WT
littermates for their basal level of cFos (as a surrogate for neuronal activation) in
orexin neurons.

Figure 4.3 Gal-LepRb neurons innervate local orexin neurons and noradrenergic LC
neurons. A. In LepRbCre mice injected with Ad-iN/WED into the LHA many WGA
neurons are co-expressed locally with orexin. B. In GalCre mice injected with AdiN/WED into the LHA many WGA neurons are co-expressed locally with orexin and
within the LC WGA neurons co-expressed TH, depicting noradrenergic neurons (C.).
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Indeed, we found that specifically the rostral portion of orexin neurons from
Gal-LepRbKO mice had a higher percentage of cFos positive orexin neurons
compared to WT littermates (Figure 4.4, A-E; n=5, pANOVA<0.003, * pHolm-Sidak<0.05).
This was due to an increased number of cFos/orexin neurons (Figure 4.4, D), while
the total number of orexin neurons was unchanged or decreased (Figure 4.4, E).
This was further confirmed with qPCR, where LHA orexin gene expression
remained unchanged between WT and Gal-LepRbKO mice (Figure 4.4, G).
Interestingly, within the LHA the gene expression of orexin receptor 2 (OX2), but
not orexin receptor 1 (OX1), was significantly decreased (Figure 4.4, G; *pttest

<0.02), suggesting that increased activation of orexin neurons may preferentially

act via OX1 in the LHA. Furthermore, we establish that orexin neurons are colabeled with GalR1 (Figure 4.4, F), further supporting that circulating (baseline)
leptin levels provide an inhibitory tone onto orexin neurons that is mediated by
galaninàGalR1 signaling (Figure 4.4, H).

4.4 DISCUSSION
Our data outline a novel neuronal circuit where Gal-LepRb neurons
directly innervate orexin neurons as well as noradrenergic neurons in the LC,
but were not found to substantially innervate the VTA directly. While leptin
stimulates inhibitory acting galanin expression in the LHA the lack of leptin
action in galanin neurons robustly decreased galanin expression, and resulted in
enhanced activation of orexin neurons.
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Figure 4.4 Enhanced orexin activation in Gal-LepRbKO mice. IHC stain of nuclear
cFos (red nuclear stain, as a surrogate for neuronal stimulation) and orexin-A
(green stain) in WT (A) and Gal-LepRbKO mice (B). C. Percentage of total orexin
neurons co-labeled for orexin and cFos in WT and Gal-LepRbKO mice; extending
from the most rostral portion of the orexin population (Section 1) to the most caudal
portion (Section 4). pANOVA<0.05; *pt-test<0.05, n=5. Total number of cFos/orexin
positive neurons (D) and total orexin cells (E) were not significantly different
between Gal-LepRbKO and WT mice. F. IHC stain of orexin-A (red) and GalR1
(green) showed orexin neurons expressed the GalR1. G. Gene expression
analysis of microdissected LHA tissue showed no difference in orexin or orexin
receptor 1 (OX1) mRNA, however orexin receptor 2 (OX2) was significantly
decreased (pttest <0.05, n=10-13). H. Hypothesized circuit establishing leptinmediated inhibition of orexin neurons via galaninàGalR1 signaling.
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In line with this observation, orexin is known to stimulate sucrose intake (Baird et al.
2009), while orexin receptor deficient mice have reduced sucrose intake (Matsuo et
al. 2011). Pharmacological blockade of orexin receptors partially prevents fastinginduced increases of palatable food intake (Rodgers et al. 2001). Thus, the
observed increase in sucrose consumption in Gal-LepRbKO mice (Chapter 3) and
increased activation of orexin neurons suggests that leptin action on LHA galanin
neurons mediates fasting induced sucrose consumption.
Importantly, Gal-LepRb neurons strongly innervate noradrenergic neurons in
the LC. Similarly, the LC is the major projection sites of orexin neurons (Peyron et
al. 1998) and control both arousal and reward (Sakurai and Mieda 2011). The LC is
the sole NE source for many central sites (e.g. prefrontal cortex, PFC), while other
sites (e.g. hypothalamus) receive additional NE input from the brainstem (NTS).
Leptin treatment decreases and leptin deficiency increases hypothalamic NE levels,
while activation of the α-2-adrenoceptor substantially increases hyperphagia in
leptin deficient obese mice (Kutlu et al. 2010, Currie and Wilson 1991, 1992, 1993).
Altogether, innervation of such prominent nuclei that regulate reward-driven
behaviors provides an intriguing circuit for future investigation of LHA-leptin action.
Importantly, our data shows that Gal-LepRb neurons utilize a novel LHA LepRb
circuit where leptin acts to inhibit orexin neurons via leptin-evoked galaninàGalR1
signaling in orexin neurons.
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CHAPTER 5. CONCLUSION
5.1 GAL-LEPRB NEURONS ARE A NOVEL LEPRB POPULATION
Through the investigation of the LHA-LepRb subpopulation, as characterized
by LepRb neurons co-expressing the inhibitory neuropeptide galanin (Gal-LepRb
neurons), our data establishes that Gal-LepRb neurons mediate anorexigenic leptin
action via modulation of reward circuits that govern nutrient intake. Gal-LepRb
neurons are stimulated by leptin and leptin-induced stimulation of galanin neurons
elicits inhibitory effects onto synapsing neurons either via the inhibitory
neurotransmitter GABA or galaninàGalR1 mediated signaling. We found that GalLepRb neurons are a distinct population from two well-established orexigenicinfluencing LHA populations: the melanin concentrating hormone (MCH) and orexin
neuronal populations. However, we did identify additional subpopulations within the
Gal-LepRb population. We show that 30% of Gal-LepRb neurons were found to
additionally express the anorexigenic peptide cocaine-amphetamine regulated
transcript (CART), as well as, a considerable portion of galanin neurons that coexpressed neurotensin (Nts).
Recently, Leinninger et al., reported on findings that characterized a LHA
LepRb subpopulation co-expressing Nts (Nts-LepRb neurons). Like Gal-LepRb
neurons, Nts-LepRb neurons innervate local orexin neurons, however, Nts-LepRb
neurons were shown to directly project to the VTA (Leinninger et al. 2011).
Importantly, Gal-LepRb neurons are distinguished from Nts-LepRb neurons, as GalLepRb neurons were not observed to project to the VTA. Furthermore, we show
that Gal-LepRb neurons innervate the noradrenergic neurons of the LC, a finding
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that was also not reported for Nts-LepRb neurons. The LC also receives dense
projections from orexin neurons (Peyron et al. 1998) and is largely recognized for
influencing arousal, addiction and withdrawal pathways (Rasmussen et al. 1990,
Nestler 1992, Kutlu et al. 2010).
Importantly, the LC was a nucleus that had yet to be identified as a potential
target of leptin action, and provides an intriguing circuit for investigating the role of
Gal-LepRb neurons in aspects of arousal, addiction and nutrient selection. For
example, we know that the LC is the sole norepinephrine (NE) source for many
central sites. Leptin deficient ob/ob mice exhibit increased hypothalamic NE levels
while leptin treatment decreases hypothalamic NE levels. Moreover, ob/ob mice
given a low dose of the α-2-adrenoceptor agonist clonidine were observed to
selectively increase carbohydrate intake {while protein and fat intake remained
unaltered (Currie and Wilson 1991)}. This would implicate a potential role for leptin
in regulating NE-mediated nutrient selection, possibly via leptinàGal-LepRbmediated inhibition of the LC. Our data indicates that Gal-LepRb neurons represent
a novel LHA LepRb population capable of mediating homeostatic mechanisms of
energy balance and reward function as proposed in the illustrated Gal-LepRb circuit
schematic shown in Figure 5.1.

5.2 GAL-LEPRB NEURONS MEDIATE APPETITIVE BEHAVIORS VIA REWARD
CIRCUITS
To establish the physiological importance of Gal-LepRb neurons we
developed a mouse model with a targeted deletion of LepRb specific to galanin
neurons; termed Gal-LepRbKO mice. We show that Gal-LepRbKO mice exhibit
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reward system as largely observed by their differential preferences for palatable
sucrose and lipid solutions and their enhanced food-motivated behaviors on the
incentive runway. There are two predominant systems governing behaviors
associated with food rewards: the mesolimbic dopamine system and the opioid
system. To gain further insight as to how these reward pathways were altered, we
compared expression profiles of markers specific to each system in Gal-LepRbKO
and WT mice. Indeed, we found that Gal-LepRbKO mice have reduced DA content
within the NAc (Figure 5.2) as well as decreased µ-opioid receptor gene expression
within the NAc and LHA (Figure 5.3).

Figure 5.1 Schematic of proposed Gal-LepRb circuit.
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Figure 5.2 Gal-LepRbKO mice have decreased dopamine content in the NAc. HPLC
detection of total dopamine content from microdissected NAc tissue (methods
described in Chapter 3) in Gal-LepRbKO and WT mice (n=7-8; pt-test <0.05).

Figure 5.3 µ-opioid receptor gene expression is decreased in the LH and NAc of
Gal-LepRbKO mice. µ-opioid receptor mRNA fold change from microdissected tissue
from the LH and NAc (n=10-13; pt-test <0.05) in Gal-LepRbKO and WT mice.
(TaqMan probes: GAPDH, housekeeping gene= Mm99999915_g1; µ-opioid
receptor Mm01188089_m1). Fold induction of gene expression was calculated
using the ΔΔCT method (refer to Chapter 3 for complete microdissection techniques
and Chapter 2 for qPCR methodology).
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It is now widely acknowledged the properties that determine the reward
value of nutrients are mediated by two distinguishable mechanisms: reward “liking”
and reward “wanting” (Berridge, Robinson, and Aldridge 2009). In this theory “liking”
refers to the pleasantness or hedonic value of food and is primarily associated with
opioid neurotransmission. On the other hand, “wanting” refers to the incentive
value or motivational properties of a given stimulus, which is primarily a function of
the mesolimbic dopaminergic system. Central pathways that regulate “liking” and
“wanting” behaviors are highly relevant for studying the underlying mechanisms
linked to diet-induced obesity. For instance, in rodent models of diet-induced
obesity higher concentrations of sucrose and lipid solutions are required to achieve
similar “liking” responses as those observed in lean individuals (Shin et al. 2011).
Therefore in obesity, a much higher threshold must be reached to attain the
expected pleasure response from palatable foods. In contrast, obesity-induced
changes in both palatable food “liking” and “wanting” responses are reversed by
leptin (Shin et al. 2011, Davis, Choi, and Benoit 2010, Figlewicz 2003, Figlewicz et
al. 2004, Figlewicz and Benoit 2009).
5.2.1 Food-motivated “wanting” and the reward deficiency hypothesis.
Activation of the mesolimbic dopaminergic system, and largely dopamine release in
the NAc (mesoaccumbal DA pathway) plays a critical role in the reinforcing and
motivational aspects attributed to reward “wanting” (Berridge and Robinson 1998,
Ostlund et al. 2011, Pecina et al. 2003). Palatable foods high in sugar are potent
stimulators of dopamine release (Hajnal, Smith, and Norgren 2004, Rada, Avena,
and Hoebel 2005). We report that Gal-LepRbKO mice exhibit a marked increase in
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their sucrose intake over lipids and demonstrate greater “wanting” for a sugary treat
on the incentive runway. However, we found that NAc DA content was significantly
reduced in Gal-LepRbKO mice compared to WT mice. This finding seemed
somewhat contradictory to our behavioral findings as we predicted DA content, if
anything, would be increased in Gal-LepRbKO mice. In light of this, we found that
decreases in mesoaccumbal DA signaling, do not always translate into reduced
reward-motivated behaviors. In fact, deficiencies in dopamine signaling are highly
correlated with addictive-like behaviors and are observed by the strong “wanting”
for a reward reinforcer (Blum et al. 2000, Comings and Blum 2000). This
phenomenon is interpreted by the reward deficiency hypothesis, which explains that
reward deficient individuals (a genetically or environmentally-induced down
regulation of DA signaling) typically experience a heightened sense of
unpleasantness even in presence of a rewarding stimulus. In order to alleviate the
perceived negative state, they generally demonstrate greater reward-seeking and
reward-taking behaviors as an attempt to restore mesoaccumbal DA signaling.
Therefore, it is possible that the reduced NAc dopamine content observed in GalLepRbKO mice is perceived as a reward deficit and thus translates into their
enhanced food-motivated behaviors. As mentioned, Gal-LepRb neurons project to
and inhibit orexin neurons. In parallel, fasting-induced decreases in circulating leptin
would likely diminish leptin’s inhibitory influence. With the removal of this inhibitory
block, orexin neurons increase their activity and thereby stimulate mesoaccumbal
DA release. In the case that orexin neurons are kept in a chronic state of activation,
as evident in Gal-LepRbKO mice, a deficient reward response is likely to manifest
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due to an exhausted mesoaccumbal DA system. However, more precise
methodology to quantify aspects of dopamine signaling (such as release, re-uptake,
synthesis, etc.) in Gal-LepRbKO mice is necessary to fully support this hypothesis.
5.2.2 Macronutrient selection and “liking”. The pleasantness or the
hedonic value attributed to food “liking” is governed by opioid neurotransmission.
Particularly signaling via the µ-opioid receptor within the NAc has been shown to
increase food intake with a predominant effect on increasing fat consumption
(Zhang, Gosnell, and Kelley 1998). Hypothalamic galanin administration also
preferentially increases fat intake (Tempel, Leibowitz, and Leibowitz 1988) and
galanin is known to influence µ-opioid receptors via GalR1 signaling in reward
pathways (Holmes et al. 2012).
Here we report that Gal-LepRbKO mice show decreased fat consumption as
assessed in a two-bottle choice test (when paired with sucrose or given alone). In
parallel with the increased fat consumption observed in animals after administration
of either galanin or µ-opioid receptor agonists, we show that LHA galanin, GalR1
and µ-opioid receptor gene expression is decreased in Gal-LepRbKO mice. Hence,
the down regulation of µ-opioid receptors and galanin signaling (specifically galanin
signaling via GalR1) likely contributes to the decreased “liking” of fats observed in
Gal-LepRbKO mice. In contrast, Gal-LepRbKO mice demonstrated a robust
preference for sucrose in the two-bottle choice test. The differential preference
exhibited by Gal-LepRbKO mice specifies that lipids are less “liked” and highlights a
potential mechanism by which galanin and µ-opioid receptor signaling selectively
defines the pleasantness perceived when fats are consumed. Thereby suggesting
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the existence of diverging circuits, which would selectively govern the hedonic
properties of sucrose or fats, respectively. Hence WT mice, with normal galanin and
µ-opioid receptor function, will demonstrate equal “liking” of sucrose and fats (as
observed in two-bottle choice test) because the competition between the diverging
circuits governing fat and sucrose intake is matched accordingly. The existence of
dissociable pathways influencing sucrose intake has also been suggested, where
the mesoaccumbal DA system drives sucrose “wanting,” in a manner that is
independent from the hedonic “liking” component of sucrose (Pecina et al. 2003).
As observed with drugs of abuse that induce abnormally high DA release, drug
addicts report higher ratings of drug “wanting,” but no longer experience pleasure or
“like” the drug (Evans et al. 2006). Similarly, addictive-like behaviors (comparable to
“wanting”) have been reported in models of sugar bingeing but not observed for fatbingeing (Hoebel et al. 2009, Avena, Rada, and Hoebel 2009). This suggests that
the behaviors mediating lipid consumption are dictated through a pathway
independent from “wanting,” and potentially involve the galanin and opioid systems.
In summary, neural circuits guiding food choice are clearly not the result of one
prevalent pathway. Instead, mechanisms driving the intake of select macronutrients
seems to be differentially regulated through distinct signaling pathways that function
to encourage food selection based on the needs of the body.
5.2.3 Implications for orexin neurons in the Gal-LepRb pathway. Orexin
has been implicated in the activation of central hedonic hotspots that increase
“liking,” as well as enhancing “wanting” for food rewards. Numerous reports provide
evidence that show the activation of orexin neurons (and when orexin is centrally
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injected) evokes reward-driven, locomotor responses (food-seeking, “wanting”)
associated with increased mesoaccumbal DA release (Choi et al. 2010, Thorpe et
al. 2005, Sharf et al. 2010, Harris, Wimmer, and Aston-Jones 2005). However,
through a distinguishable circuit, the pleasantness or “liking” of palatable foods is
amplified via opioid signaling within distinct hedonic “hotspots”. Projections from
orexin neurons to one such “hotspot,” the ventral pallidum, holds implications for the
divergent actions of orexin to regulate different aspects of nutrient reward. A recent
study showed that injections of the orexin peptide into the ventral pallidum induced
a marked increase of positive “liking” reactions to sucrose solutions, but had no
effect sucrose “wanting” (Ho and Berridge 2013). Thus, orexin signaling within this
distinct hedonic nucleus influences opioid-mediated “liking” responses. Moreover,
µ-opioid receptors are expressed on orexin neurons (Georgescu et al. 2003), and
endogenous opioids are required for orexin-mediated feeding (Clegg et al. 2002).
Indeed, the activation of NAc µ-opioid receptors amplifies “liking” reactions and
increases food intake. µ-opioid receptor activation in the NAc also increases the
activity of orexin neurons. However, when orexin receptors in the VTA are blocked,
food intake is no longer increased by NAc µ-opioid receptor activation (Zheng,
Patterson, and Berthoud 2007). Taken together, orexin neurons appear to serve as
a hub for the integration of signals relaying nutritional status (i.e. fasting/ or low
leptin) and information regarding the value of a food reward. This signal
convergence is then translated into specific appetitive behaviors based orexin’s
distinct anatomical projection targets to effect both reward “liking” (via µ-opioid
receptors in hedonic nuclei) and reward “wanting” (via mesoaccumbal DA pathway).
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In light of this, we know that leptin reduces palatable food “liking” and
“wanting” behaviors, and these effects are most likely the outcome of leptinmediated inhibition of orexin neurons. Consistent with previous findings (Leinninger
et al. 2009, Louis et al. 2010), we confirmed that LepRbs are not expressed on
orexin neurons, demonstrating that leptin inhibits orexin neurons indirectly.	
  But the
LepRb population that mediates this inhibitory leptin effect onto orexin neurons is
unknown.
The here presented work shows convincing evidence that Gal-LepRb
neurons in the LHA mediate an inhibitory effect onto orexin neurons. As we found
that abolishing leptin signaling exclusively in galanin neurons increases the
activation level of orexin neurons. Consistent with this, Gal-LepRbKO mice show
enhanced motivation to obtain a sugary food reward on the incentive runway. Our
data further establishes a functional circuit responsible for mediating these effects.
We show that leptin stimulates GABAergic Gal-LepRb neurons, promoting synaptic
release of the inhibitory neuropeptide galanin (and/or the inhibitory
neurotransmitter, GABA). Gal-LepRb neurons innervate local orexin neurons.
Additionally, we determined that orexin neurons express the Gi-coupled GPCR
galanin 1-receptor (GalR1), validating the cellular ability of orexin neurons to
respond to inhibitory galanin action. Altogether, these data demonstrate that leptinmediated galanin release from LHA Gal-LepRb neurons mediates the inhibitory
tone onto orexin neurons. Our findings reveal that Gal-LepRb neurons are a novel
LHA LepRb population that regulates the rewarding value of nutrients via control of
orexin neurons.
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